MEDICAL EVALUATION FIELD MANUAL

ĺ

Prepared for the
California Department of Mental Health
And
Local Mental Health Programs
Pursuant to Chapter 376, Statutes of 1988
Assembly Bill 1877

by

Lorrin M. Koran, M.D.
Department of Psychiatry and Behavioral Sciences
Stanford University Medical Center
Stanford, California
1991



MEDICAL EVALUATION FIELD MANUAL

Prepared for the
California Department of Mental Health
And
Local Mental Health Programs
Pursuant to Chapter 376, Statutes of 1988
Assembly Bill 1877

by

Lorrin M. Koran, M.D.

Department of Psychiatry and Behavioral Sciences
Stanford University Medical Center
Stanford, California
1991

TABLE OF CONTENTS

INTRODUCTION AND RATIONALE	4
WHERE TO SCREEN: RECOMMENDED SETTINGS	8
HOW TO SCREEN	
When a Complete Examination is Used	12
When the SB 929 Screening Algorithm is Used	15
Arranging for Follow-up Medical Care	21
RECORDING THE RESULTS OF SCREENING	
The Standard Medical History Form	2 4
The Essential Medical Information Form	27
The Physical Examination Record	29
FACILITATING PROGRAM STAFF ACCEPTANCE OF SCREENING	32
WHO SHOULD SCREEN	
Qualifications for Clinical Staff	3 5
Qualifications for Clerical Staff	39
Qualifications of a Medical Consultant	41
COSTS OF SCREENING	
Fiscal Aspects of a Screening Program	43
Contracting With a Laboratory Service	45
CLUES SUGGESTING THAT MENTAL SYMPTOMS HAVE AN ORGANIC CAUSE	48
REFERENCES	50
APPENDIX A: SAMPLE FORMS FOR RECORDING PATIENT DATA	
APPENDIX B: SCIENTIFIC PUBLICATIONS FROM THE SB 925 STUDY	

ACKNOWLEDGMENTS

The author wishes to express his deep appreciation for critical readings of drafts of this Field Manual and for thoughtful suggestions to:

Harold C. Sox, Jr., M.D, and Keith I. Marton, coinvestigators for the SB 929 Study. Dr. Sox and Dr. Marton contributed many of the ideas embodied in this Field Manual and helped to elucidate these ideas through their comments on drafts of the Manual.

Ken Meinhardt, M.D. and Yvette Sheline, M.D., of the Santa Clara County Bureau of Mental Health,

Eric M. Jacobson, M.D., John Blossom, M.D., Michael W. Brady, M.D., John A. Sponsler, M.D., Captane P. Thomsom, M.D., and Ms. Kris Calvin of the Committee on Mental Health of the California Medical Association,

Michael E. Meek, M.D. and Ms. Sue North, of the Government Affairs Committee of the California Psychiatric Association,

Stephen N. Wilson, M.D., Alan Albright, M.F.C.C., Alex Anagnos, R.N., M.S., Cynthia Bloomfield, L.C.S.W., R.W. Burgoyne, M.D., Bill Goggin, L.C.S.W., M.F.C.C., Jim Gordon, L.C.S.W., Fred Hawley, R.N., Terrell Hedstrom, R.N., Arnaldo Moreno, M.D., Josie Romero, L.C.S.W., Stan Taubman, L.C.S.W., John Wells, M.D., all of the Clinical Services Committee of the California Conference of Local Mental Health Directors.

Ultimate responsibility for the content of this Field Manual rests with the author, who hopes that it will contribute to better patient care.

INTRODUCTION AND RATIONALE

This Field Manual shows California mental health program administrators and staff how to screen their patients for active, important physical diseases. The Manual explains how, where and when to screen, how to initiate and staff a screening program, and how to maximize its cost-effectiveness. The Manual also includes a list of clinical findings that characterize patients whose mental symptoms are quite likely to be caused by an unrecognized physical disease.

For several reasons, mental health professionals working within a mental health system have a professional and a legal obligation to recognize the presence of physical disease in their patients. First, physical diseases may cause a patient's mental disorder. Second, physical disease may worsen a mental disorder, either by affecting brain function or by giving rise to a psychopathologic reaction. Third, mentally ill patients are often unable or unwilling to seek medical care and may harbor a great deal of undiscovered physical disease. Finally, a patient's visit to a mental health program creates an opportunity to screen for physical disease in a symptomatic population. The yield of disease from such screening is usually higher than the yield in an asymptomatic population.

This Manual was developed from the methods and results of the California Medical Evaluation Study carried out in 1983 and 1984. The study was authorized by Senate Bill 929 (Chapter 208, Statutes of 1982). The methods and results of the SB 929 study have been reported in detail to the California Legislature and in several scientific publications 29.32.48 that are included in Appendix B of this Field Manual.

The SB 929 study team performed complete medical evaluations of 476 patients drawn from 24 county mental health programs spread across four Northern California counties and of 53 patients at Napa State Hospital. The most important findings of that study are: 31,32

- 1. Nearly two out of five patients (39%) had an active, important physical disease.
- 2. The mental health system had failed to detect these diseases in nearly half (47.5%) of the affected patients.
- 3. Of all the patients examined, one in six had a physical disease that was related to his or her mental disorder, either causing or exacerbating that disorder.
- 4. The mental health system had failed to detect one in six physical diseases that were causing a patient's mental disorder. (Five of 32 cases of physical disease causing a mental disorder had not been detected.)
- 5. The mental health system had failed to detect more than half of the physical diseases that were exacerbating a patient's mental disorder. (Twenty-seven of 49 cases of physical disease exacerbating a mental disorder had not been detected.)
- 6. Screening the SB 929 patients cared for in county mental health programs caused neither a net increase nor a net decrease

in the state's combined medical and mental health costs for these patients in the year after screening compared to the year before screening.

These results are consistent with those of studies in other mental health settings (Appendix B, Table 1). These studies have reported that from 15% to 93% of mentally ill patients had a concomitant, active, important physical disease. From 4% to 80% of patients had a physical disease that was detected initially through screening carried out by the mental health program. From 4% to 32% of patients had a physical disease that was either causing or exacerbating their mental disorder.

These findings underscore the need to improve screening for physical disease among patients in California's public mental health system. The screening methods now in use, ranging from very limited to moderately complete medical histories and physical examinations, often do not detect important physical disease and are not very cost-effective.

To facilitate improved screening, the SB 929 study team developed a screening algorithm that uses a limited set of items from a patient's medical history, a blood pressure measurement, and selected laboratory tests to detect physical disease. (An algorithm is a set of step-by-step instructions for solving a problem.) The algorithm detected more physical diseases than the mental health programs had detected among the SB 929 patient sample, did so at a lower cost per diagnosed case, and can be performed by mental health personnel after very limited training.

A detailed description of the development and results of the algorithm, including measures of its cost-effectiveness, is included in Appendix B.⁴⁸ The body of this Field Manual describes the content of the algorithm, how to set up a screening program, and the procedures for deciding which of the algorithm's six steps to implement.

For mental health programs that wish to screen for physical disease by means of complete medical evaluations, the Appendix to this Manual includes a recommended Standard Medical History Form to be completed by patients and a recommended Standard Physical Examination Record Form for recording the results of physical examinations performed by clinical staff. Other medical history and physical examination forms are included as additional sources for mental health program staff who wish to design their cwn forms.

WHERE TO SCREEN: RECOMMENDED SETTINGS FOR SCREENING

Inpatient Settings and Hospital Emergency Rooms

As a matter of law, regulation or policy, screening for physical disease within California's public mental health system already takes place in local hospitals, psychiatric health facilities, state hospitals, skilled nursing facilities and some crisis programs (e.g., in hospital emergency rooms). Unfortunately, the medical evaluations may not be careful or thorough, as indicated by the large number of patients with previously unrecognized physical disease that the SB 929 Study discovered in these settings.

To improve the quality of evaluation in these settings:

- 1. Require that the clinical staff use the SB 929 Standard Medical History Form (Appendix A) and a standardized, detailed Physical Examination Record (Appendix A). If the program's physicians do not wish to use standardized forms, evaluate the content and the consistency of their screening procedures through peer review and quality assurance procedures.
- 2. Teach the clinical staff to obtain a complete medical history from mentally disordered patients and to perform a complete and accurate physical examination.
- 3. Audit periodically the Standard Medical History Forms and Physical Examination Records to evaluate the percentage of patients with completed Forms and the percentage of questions answered on completed forms. Audit the frequency with which

staff follow up the medical problems identified by screening.

The facility's administrative and clinical program chiefs should review the audit reports.

Outpatient Mental Health Programs

Outpatients in mental health settings are seldom evauated medically. The aim of screening outpatients is to detect physical diseases that can:

- quickly become life threatening
- masquerade as mental disorders
- exacerbate mental disorders
- interact adversely with psychotropic medications
- pose significant long-term health consequences,
 especially if the disease is spread by person-to-person contact (e.g., viral hepatitis).
- expose the mental health program to liability for negligence and malfeasance due to failure to diagnose.

Routine screening for physical disease in these programs should be initiated using the SB 929 medical screening algorithm, described subsequently. Using the SB 929 screening algorithm is much less costly than complete medical evaluations, and can detect up to 90% of the physical disease detected by complete evaluations.⁴⁸

Outpatient programs should consider the pros and cons of performing routine screening for physical disease at the first versus the second or third outpatient visit. At many sites, up

to half of outpatients do not return for a second visit and do not, therefore, establish an ongoing therapeutic relationship.

Successfully referring such patients for follow-up of suspected physical illness would entail insuperable logistic difficulties.

Since detecting physical disease in outpatients is seldom an emergency, and since disease is easy to detect when it is serious enough to constitute an emergeny, routine screening of outpatients might well be delayed until the second or third visit. The choice between screening at the second or the third visit should be guided by the proportion of second visit patients who make third visits. If the proportion is high, screening can be carried out at the second visit. If it is low, screening should be delayed to the third visit so that referrals for complete medical evaluation, when indicated, can be accomplished.

Day Treatment and Community Care Settings

Patients entering day treatment and community care programs may have had a recent medical evaluation in an inpatient setting. Day treatment and community care programs should make arrangements with inpatient programs to receive a copy of this medical evaluation when the patient is transferred for continuing care. Patients who have not had a recent medical evaluation, (i.e., within the past two months), should be screened by means of the SB 929 screening algorithm or a complete medical history and physical examination.

Re-screening Readmitted Patients

Existing regulations and policies govern the medical evaluation of patients readmitted after a brief interval to local hospitals, psychiatric health facilities, state hospitals, skilled nursing facilities and some crisis programs (e.g., hospital emergency rooms). Again, reevaluations should be careful and thorough, since exposure to infectious, toxic, traumatic or other disease-producing agents or processes can have taken place.

In outpatient, day treatment and community care settings, the extent of screening should depend on the interval since a previous screening evaluation. Obtain the SB 929 screening algorithm's medical history items and blood pressure determination if more than two months have elapsed since the patient's last visit. If less than two months have elapsed, the patient's therapist should inquire about the patient's physical health status and source of medical care, as indicated on the Essential Medical Information Form. If six months have elapsed, obtain the SB 929 screening algorithm's laboratory panel as well.

HOW TO SCREEN: WHEN A COMPLETE EXAMINATION IS USED

Screening for important physical diseases may take the form of a complete medical evaluation or of the SB 929 screening algorithm. The choice between these options may depend on the kind of mental health program, e.g., inpatient versus outpatient, and on factors unique to individual facilities.

When the Screening Procedure is a Complete Medical Evaluation:

The patient should complete the Standard Medical History Form (Appendix A). Provide the patient with assistance if his or her condition interferes with understanding or attention span. Perform a complete physical examination, including a detailed neurological examination and genital and rectal examinations unless contraindicated by the patient's psychiatric condition. 2 Record the results of the physical examination on a Standard Physical Examination Record (Appendix A). Obtain a battery of Programs that employ medical or nursing staff laboratory tests. or a physician's assistant can arrange blood drawing on site. Other programs should contract with a local hospital or laboratory for phlebotomy services. The physician carrying out the screening or the consulting internist, when a nurse practitioner or a physician's assistant does the screening examination, should decide which laboratory tests to include.

Mental health programs that employ a nurse practitioner or physician's assistant to perform physical examinations should measure the reliability and validity of their examinations by

requiring the program's internal medicine consultant or another physician to observe approximately ten patient examinations and corroborate the findings.

The SB 929 Study utilized an extensive battery of laboratory tests in order to minimize the possibility of missing instances of important physical disease. The tests included:

- a complete blood count
- a 23-item chemistry panel (including determinations for glucose, albumin, serum urea nitrogen, creatinine, calcium, phosphate, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, bilirubin, iron, and electrolytes)
- a serum fluorescent treponemal antibody test
- thyroid tests (a triiodothyronine resin uptake, total serum thyroxine, and a free-thyroxine index),
- serum folate and vitamin B₁, levels
- a dipstick urinalysis.

The mental health program could select a somewhat less extensive, but still reasonable, screening battery with the advice of a specialist in internal medicine. For example, the thyroid screening test could be limited to the sensitive thyroid stimulating hormone assay or to a measurement of serum free thyroxin.

If the laboratory test panel includes a complete blood count, chemistry panel, thyroid panel, and urinalysis (without

microscopic exam), it will lead to new, previously unsuspected diagnoses or to changes in psychiatric treatment in from 1% of patients^{13,28,51,52} to as many as 6.4%, 8 8%, 49 12%, 17 or 28% of patients.

The benefits of laboratory testing in the context of a screening program include:51

- increasing physician confidence when mental illness impairs the patient's cooperation in providing a reliable history and physical examination.
- detecting physical diseases that were not suspected on the basis of the history and physical examination.
- assisting in differential diagnosis.
- providing reassurance to patients.

A skilled physician should evaluate abnormal test results in the context of other information about the patient. False positive screening tests are common in people with few or no symptoms of physical disease, and the decision to carry out or not carry out further evaluation often requires sophisticated clinical judgment.

HOW TO SCREEN: WHEN THE SB 929 ALGORITHM IS USED

The SB 929 screening algorithm has several appealing characteristics:

- 1. it is limited to those findings that best predicted the presence of physical disease in a sample of patients cared for within the California public mental health system.
- 2. it saves the effort and expense of gathering data that may not help in detecting physical disease.
- 3. the data used in the algorithm can be obtained by mental health staff and do not require a physician, nurse or physician's assistant.
- 4. the algorithm tells the user how to interpret abnormal findings as indicators of the probability of the presence of physical disease and whether to refer the patient for a complete medical evaluation.


When the Screening Procedure is the SB 929 Screening Algorithm:


The SB 929 medical algorithm requires 10 items of medical history, measurement of blood pressure, and 16 laboratory tests (13 blood tests and 3 urine tests). These data were the only strong predictors of physical disease in the SB 929 patients.⁴⁸

The county mental health department must decide whether to gather all of this information or just part of it and whether to add questions that have not been investigated as screening

items. (The California SB 929 Study did not ask about the use of alcohol, illicit drugs and prescription drugs). This decision will be influenced by the trade-offs between maximizing the probability that a patient referred for further evaluation will have an important physical disease, maximizing the proportion of truly sick patients that the screening program detects, and the program's budget. These trade-offs, in turn, are influenced by the perceived costs of failing to detect important physical disease, the perceived costs of sending well patients for evaluations, and the perceived value of detecting important physical disease. Fortunately, the SB 929 Study results (Appendix B) provide much of the data needed to make these judgments.

To maximize the probability that referred patients will be found to have an important physical disease, one would gather only enough information for algorithm steps A and B in Figure 1. The odds are high that a physical disease is present if any item in step A or step B is abnormal, 6.4 to 1 for step A and 5.7 to 1 for step B in the SB 929 patient sample. That is, if an SB 929 patient had any of the abnormal findings in step A, that individual was 6.4 times as likely to have a physical disease as were individuals who did not have any of the abnormal findings within step A. This information is conveyed by the likelihood ratio of 6.4, which is shown to the right of NODE A in Figure 1. (An example of how to use the likelihood ratios to estimate the odds of disease being present in patients in different treatment





settings is presented in Appendix B. 48, p. 1272)

The costs of screening using only steps A and B are low since only inexpensive laboratory tests are required (a serum T4, hematocrit, white blood count, serum aspartate aminotransferase, serum albumin, serum calcium, and urine dipstick tests for glycosuria and hematuria). However, step A detects only 20% of patients with important physical disease, and step A and B together detect only 47% of such patients. To maximize the proportion of truly sick patients detected by the screening program, one would gather all of the information required through step F. Ninety percent of truly sick patients will have at least one of the findings in steps A through F, and will, therefore, be referred for evaluation by a physician.

Methods for estimating the cost and the cost-effectiveness of the six branch nodes, or steps, embedded in the SB 929 screening algorithm are detailed elsewhere (Appendix B). With these data, a mental health program director can calculate the costs of continuing through each step of the algorithm and decide which steps are within the program's budget.

To obtain all the data needed for the SB 929 screening algorithm, the screening program nurse, nurse practitioner or physician's assistant should:

- 1. ask the patient to complete the 10-item Medical History Checklist, assisting the patient as necessary,
 - 2. obtain a sitting blood pressure measurement,
 - 3. request the patient to provide a urine sample, and

4. draw the blood specimens for the laboratory battery.

The laboratory panel of tests should consist of:

- 1. a hematocrit
- 2. white blood cell count
- 3. serum aspartate aminotransferase
- 4. serum alanine aminotransferase
- 5. serum albumin
- 6. serum calcium
- 7. serum sodium and potassium
- 8. serum cholesterol and triglycerides
- 9. serum T4 and free T4, and
- 10. serum vitamin B₁₂.

Mental health programs that do not employ medical or nursing staff may prefer to send the patient to a local laboratory for blood drawing. The patient's urine should be examined by dipstick for glucose, blood and protein.

The items of information obtained from this screening procedure should be grouped according to the six-step algorithm shown in Figure 1. The reason for grouping the information as shown is to help interpret abnormal findings. Abnormal findings listed in the earlier steps of the algorithm more strongly predict the presence of physical disease than those occurring in later steps and hence more urgently require a physician's attention. A patient who has any positive finding from any step in the algorithm should be referred for further evaluation to a

physician who specializes in internal medicine or family medicine.

Because further medical evaluation takes place as a result of a physician's judgment (the physician who authorized the screening program or who serves as its consultant), the cost of the further evaluation is billable to third party payers. The clinical staff of the mental health program can arrange the referral, which, for insurance purposes, does not require further review by a physician. The mental health program should provide the evaluating physician with a copy of all medical information available regarding the patient and with information regarding the patient's psychiatric diagnosis, mental status, and psychotropic medications.

The SB 929 screening algorithm was validated by applying it to the clinical findings of the last 166 patients to be enrolled in the SB 929 study. However, it has not been studied in an entirely separate population. Moreover, the SB 929 patients were not completely representative of California's statewide population of public mental health patients. For example, the legislation authorizing the SB 929 study required that the study exclude patients with a primary diagnosis of alcoholism. For these reasons, county mental health policy makers should regard the SB 929 screening algorithm as tentative until it has been validated in their setting. Adding items to screen for alcohol or substance abuse, for example, may be helpful.

A county mental health department that decides to employ

the algorithm may wish to evaluate its validity by comparing referral decisions generated by the algorithm with the results of careful, complete medical evaluations of the same patients. This comparison will allow an estimate of the algorithm's false negative rate (missed diagnosis rate). The mental health policy maker should seek a statistician's advice regarding sample size and study design. Several articles are available to guide a validation study. 40.42,47,50

HOW TO SCREEN: ARRANGING FOR FOLLOW-UP MEDICAL CARE

Patients with mental disorders often fail to seek recommended medical care, whether because of inertia related to depression, paranoia related to psychotic disorders, or denial or unrealistic fears related to anxiety disorders. Steps should be taken to make it as easy as possible for patients to see the referral physician. These steps include:

- 1. explaining the reason for the referral,
- 2. asking the patient about any concerns he or she has about the referral,
- 3. helping the patient, as necessary, to complete the Statement of Facts for Medi-Cal and the related Rights and Responsibilities Form,
- 4. helping the patient, as necessary, to make the appointment,
- 5. giving the patient written confirmation of the telephone number and address of the physician to whom he or she is being referred (if this is not the patient's regular physician),
- 6. providing the patient with information about the cost of further evaluation,
 - 7. helping the patient arrange transportation, and,
- 8. estabishing a panel of physicians who are willing to carry out these evaluations for mentally disordered patients.

The mental health facility staff, rather than the screening program staff, should bear this responsibility, since the

facility staff will have on-going contact with the patient and can help resolve any referral-related problems.

Mental health facility staff should check with the patient to be sure that the consultation has been completed and should arrange to receive results of the consultation. The staff need these results because newly diagnosed illnesses or newly prescribed medications may influence the mental health treatment plan, (e.g., illnesses and nonpsychiatric medications can interact with the patient's psychotropic medications).

In view of the constraints affecting public funding of health and mental health care, county programs should strive to exchange services. If the county operates a medical clinic, the mental health program director should negotiate an arrangement for patients enrolled in the mental health program to receive medical evaluations and continuing care at the medical clinic. In exchange, the mental health program can offer mental health consultations for patients under care at the medical clinic. The health and mental health departments could even agree to share clinical staff or arrange other linkages.

Written agreements describing linkages should detail joint authorities, responsibilities and benefits.³⁷ The agreements should address who pays which costs, who collects and retains fees, whose personnel policies determine staff roles and financial arrangements, and who collects, stores and reports which information. Smooth relationships between county health and mental health programs are particularly important for

patients who receive medical care under county auspices (medically indigent adults) and for those funded by Medi-Cal.

The screening program will generate a steady stream of patients needing medical evaluation. In counties without county-operated health programs, the mental health program director should negotiate an agreement with a panel of primary care physicians to evaluate a limited number of Medi-Cal or indigent patients each month. Setting a limit can prevent the primary care physicians from feeling overwhelmed by the potential for a large volume of low-fee or indigent patients.

Does the county mental health department, in mounting a screening program, become legally liable when a patient is unable to obtain recommended follow-up care? The answer is unclear, but is probably, "No." Mounting a physical disease screening program in settings other than emergency rooms and inpatient facilities is beyond the standard of community mental health care, so that failure of such a screening program to ensure perfect results would not be not evidence of negligence. The county's responsibility probably ends with informing legally competent patients and the conservators of incompetent patients who are not receiving emergency or inpatient care that they should seek further evaluation. County counsel's advice should be sought, however, on this point. In emergency room and inpatient settings, inadequate medical evaluation can result in findings of liability.

RECORDING SCREENING RESULTS: THE STANDARD MEDICAL HISTORY FORM

The SB 929 Medical Evaluation Study found that medical histories recorded in patients' clinical records, even in inpatient settings where physicians were employed, were often inadequate, exceedingly brief, and omitted much important information. Therefore, the Study team recommended that this Manual include a Standard Medical History Form to be used in facilities where medical evaluation already takes place (inpatient units, psychiatric health facilities, state mental hospitals and skilled nursing facilities).

Recommendations Regarding the Standard Medical History Form

- 1. Adopt the SB 929 Medical History Form. County mental health departments should adopt as their Standard Medical History Form the form developed for the SB 929 Study (Appendix A), with modifications needed for recording administrative data, demographic data, and the history of any current physical illness. The caregiver should fill out this Form, suitably modified to meet local needs, when a patient is admitted to an inpatient unit, psychiatric health facility, or county-funded skilled nursing facility. The State Department of Mental Health should substitute the Standard Medical History Form for forms MH 5705 (11/82) and MH 5705A (686), now used in the state mental hospitals.
- 2. Carry out periodic audits. The medical records departments in these facilities should carry out periodic audits

of the Standard Medical History Forms to measure the percentage of patients for whom a Form has been used and the percentage of questions answered on the forms. The facility's quality assurance committees should audit the frequency with which identified problems have been followed up appropriately.

- 3. Arrange for a physician to review each patient's medical history. During the review of each patient's Initial Treatment Plan, a physician should review the Standard Medical History Form as part of the quality assurance plan required by Medi-Cal.
- 4. Send a copy of the patient's medical findings with any patient who is transferred. A copy of the Standard Medical History Form, Physical Examination Record and all recent laboratory test results should accompany each patient who is transferred from one mental health program to another. This practice will prevent duplication of effort, raise the quality of care and decrease the costs of care. Mental health programs should also send these records when referring a patient for evaluation of suspected physical disease.

Recommendations Regarding the SB 929 Medical History Checklist

If the screening program uses just the algorithm developed by the SB 929 Medical Evaluation Study, then it needs to collect only ten items of medical history. A Medical History Checklist incorporating these ten items appears in Appendix A. If the patient responds "yes" to any of these items, he or she should be referred for further medical evaluation. The patient can complete

the Checklist or the screening program's staff can administer it as a brief questionnaire.

To assist county mental health programs in adapting the SB 929 Standard Medical History Form and Physical Examination Record, several other model medical forms are included in Appendix A. These include the forms used in the Veterans Administration clinics and hospitals, the Northern California Permanente Medical Group, Inc., and several commercially available forms.

RECORDING SCREENING RESULTS:

THE ESSENTIAL MEDICAL INFORMATION FORM

Too often, a patient's medical problems, uncovered in earlier treatment episodes, lie buried in unexamined parts of the patient's clinical record. In order to increase staff awareness of patients' medical problems, the county mental health department should develop an Essential Medical Information Form. The Form should include information about any past medical problems. These include problems that might cause or exacerbate the patient's mental disorder, require on-going treatment or interact with psychotropic drug treatments. Placing the Form directly behind the clinical record's Face Sheet at the mental health facility would bring the information to staff attention. The Form should be brightly colored for easy recognition and printed on heavy stock (e.g., 65 pound cover stock) for durability.

The Essential Medical Information Form should include:

- 1. identifying data.
- 2. active physical diseases and problems as confirmed by a physician.
- 3. currently suspected physical diseases and problems that have not been confirmed by a physician.
- 4. prescribed drugs currently taken, including drug name, unit dose, total daily dose and date this information was noted.
 - 5. current alcohol, illicit drug, tobacco and caffeine use.

- 6. past history of alcohol or other substance abuse or dependence with approximate date of last episode.
- 7. current regular use of any over-the-counter medications, sleeping remedies, cold preparations, or pain relievers.
- 8. past history of physical diseases, injuries, and operations.
- 9. the name, address and telephone number of the health care provider(s) caring for the patient, if any. If none, record "None."
- 10. the name and address of health care providers, including hospitals, that have a written record of the patient's past medical care.
- 11. the name of the person who entered the data on the Essential Medical Information Form and the date of entry.

Space should be provided for adding new information about the patient's active physical diseases, suspected physical diseases, prescribed drugs, alcohol and other substance use, and regular use of over-the-counter medications, since these can change rapidly.

California Department of Mental Health Letter 80-18 (June 30, 1980) states that a non-physician can record a history of physical disease or a suspected medical diagnosis in a patient's clinical record.

RECORDING SCREENING RESULTS: THE PHYSICAL EXAMINATION RECORD

The SB 929 Study found many examples of incompletely recorded physical examinations recorded in patients' clinical records in 24-hour hospitals and psychiatric health facilities. Furthermore, the record often did not contain important signs of physical disease that the SB 929 Study clinical team found in its complete examinations. From 17% to 25% of patients in various 24-hour hospitals and psychiatric health facilities had incomplete physical examinations recorded in their charts. The absence of a genital or rectal examination did not result in the physical examination being classified as "incomplete."

A neurologic examination was not recorded in 45% of hospitalized patients. This omission is of particular concern because of the high frequency with which neurologic disorders induce psychiatric signs and symptoms. Fully 80% of the 529 patients examined in the SB 929 study had neurologic abnormalities (many induced by psychotropic medications). Eleven patients (2.2%) had important neurological diseases newly detected by the SB 929 study team, including three cases of epilepsy. 30

The physical examination often contributes findings that lead to a change in a psychiatric patient's diagnosis or treatment. Koranyi found that 12% of psychiatric outpatients had an unrevealing medical history, but manifested physical examination findings that changed their psychiatric diagnosis or

treatment.33 Chandler and Gerndt, in a study of 224 consecutive admissions to the University of Iowa Psychiatric Hospital, found that the physical examination contributed to a change in psychiatric diagnosis or treatment in 14 patients (6%).7 Fitzgerald, in a review of published studies, describes the clinical situations and body systems in which the physical examination is likely to be highly accurate and those in which modern technology has provided a superior means of gathering evidence of abnormality. 14 For example, careful physical examination is accurate in detecting anemia and valvular heart disease, but is inferior to technical studies in detecting obstructive lung disease and abdominal aortic aneurysms. Physical examination reveals which patients should receive computed tomography scans after head trauma or after alcohol withdrawal seizures, and, together with a medical history, appears to be the best method for evaluating syncope.

Appendix A contains several forms for recording the results of a complete physical examination. Using these forms as models, the county mental health department should design a standard form and mandate its use. The SB929 Physical Examination Record provides a good model: it lists in checkoff form many signs of physical diseases that can cause or exacerbate mental symptoms; it includes a very detailed list of neurological findings; it is suitable for use by a nurse practitioner or physician assistant; it allows easy entry of coded findings into a computer data base.

The Veterans Administration physical examination form (VA

Form 10-7978e, revised April, 1989) has less explicit description of physical findings than the SB 929 Form. It is more suitable for use by a physician, who would record abnormalities briefly in the space provided for each organ or system. The neurological portion of this form should be expanded to include neurological abnormalities that are likely to be encountered in psychiatric patients. The neurological portion of the SB 929 Physical Examination Record can serve as a model.

The forms used to record physical examinations at Napa State Hospital (MH 5731, revised 6/86) and at Agnews Development Center (DS 5630, revised 12/84) are included for reference purposes. The Napa State Hospital form, like the SB 929 Physical Examination Record, lists abnormal signs that can be circled to record their presence.

FACILITATING PROGRAM_STAFF ACCEPTANCE OF SCREENING

Introducing change in an organization is an art. People resis change because it demands attention and energy and because the advantages of new procedures are not always apparent to those who are asked to change their routines. Mental health facility staff may resist the introduction of a medical screening program because it creates additional work, interferes with mental health program activities or represents the threat of uncovering errors in diagnosis (having failed to detect physical diseases masquerading as mental disorders). Program leaders can take several steps to minimize staff resistance.

First, motivate the staff by teaching them about the prevalence of physical disease in patients with mental disorders. The data presented in Appendix B of this Manual may be a helpful starting place. No one wants to perpetuate bad care and these data should motivate the staff. The data can be displayed in poster form, distributed in a memo, and discussed at staff meetings. Nonmedical staff need to become aware that physical diseases often cause or exacerbate mental disorders.

Second, state explicitly the mental health program's obligations. Help the staff understand that helping patients, especially chronically mentally ill patients, with their basic health needs is as much a part of community-based mental health care as is helping them with social supports, protection, housing and transportation.

Third, involve the staff in planning. Let them decide how to integrate the screening program into the activities of the mental health program.

Fourth, allay fears. Assure the staff that the discovery of unsuspected physical disease by the screening program will not result in negative staff evaluations.

Fifth, create incentives. Devise a system for rewarding staff members for recognizing physical disease and for taking the presence of physical disease into account in mental health treatment plans.

Sixth, provide feedback about successes. Inform the staff when treatment of a physical disorder leads to improvement in a patient's mental condition. A monthly review of successful medical interventions could help maintain staff support for the screening program.

Seventh, set goals. In an inpatient setting, for example, the goal might be: all patients will receive a complete medical evaluation within 24 hours of admission. In an outpatient clinic, the goal might be: all patients will be evaluated by means of the SB 929 screening algorithm at the time of their second clinic visit. The facility should audit the degree of goal attainment quarterly and review these audits with the county mental health department.

Finally, announce leadership support of the program. Inform the staff that the leadership, both at the facility level and at the level of the county mental health department, support the

screening program. Support can take the form of statements mandating a policy of screening patients.

The administrative lines of authority for screening staff must be clear in order to minimize conflict with the staff who are engaged in delivering mental health services. If the screening staff are based full time at a given facility, they should be accountable administratively through the facility's chain of command. If, however, the screening staff visit many sites, they should report administratively to a centrally located administrator of the screening program. To prevent inter-staff conflict, this administrator, who reports to the county mental health director, must negotiate written agreements with the administrators of each screening site.

WHO SHOULD SCREEN: QUALIFICATIONS FOR CLINICAL STAFF

The screening program involves both clinical and clerical tasks. In some settings, the screening program's activities can be carried out by existing staff. Their job descriptions should be revised to reflect their screening responsibilities.

Qualifications for Clinical Staff

Anyone can learn too obtain the data required for the screening algorithm described in this Manual: the patient's blood pressure, the results of laboratory tests, and ten items of medical history. Nurses or physician's assistants can gather these data, since they are competent to draw and prepare blood for testing. Nonmedical staff can be trained to measure blood pressure and to perform a venipuncture, or the patient can be sent to a local laboratory for blood tests. In measuring blood pressure, the staff should attend to those factors that can influence the measurement, including cuff size, arm position, and pressure of the head of the stethoscope on the artery. 14

If the county wishes to mount an outpatient screening program that includes a complete physical examination, it can employ nurse practitioners or physician's assistants, with an internist providing supervisory consultation.⁴⁶

Screening by Using the SB 929 Screening Algorithm

When the screening program is limited to the SB 929 screening algorithm, the nurse's or physician's assistant's job description should include the following responsibilities:

- 1. Obtains the patient's signature on a release of information form so that the screening program can release data to health care providers or request data from them.
- 2. Asks the patient to complete the Medical History Checklist and helps the patient if necessary.
 - 3. Obtains the patient's sitting blood pressure.
- 4. Completes test ordering and billing information on the laboratory test order form, identifying the laboratory tests to be billed to a third party because they are clinically indicated (see pp. 41-42).
- 5. Draws and prepares a blood sample for screening tests and sends it to a laboratory.
- 6. Obtains a urine sample, does a dipstick urinalysis, and records the results.
- 7. Notifies the clerical staff when to order laboratory and other supplies.
- 8. For patients referred for complete evaluation based on the results of the screening examination, writes a letter to the referral physician indicating the reasons for the referral and sends the results of the screening examination.
 - 9. Maintains a log of patients screened and tests ordered.

Screening by Means of a Complete History, Physical Examination and Diagnostic Test Panel

When the screening program includes a complete examination, the nurse practitioner or physician's assistant should be trained to a high degree of competence in the following skills:

- 1. recognizing psychiatric signs and symptoms
- 2. eliciting mental status findings that suggest impaired brain function (the Mini-Mental State Examination¹⁵ is an appropriate, structured screening examination.)
- 3. performing a complete, accurate, and reliable physical examination. (Depending on the patient's mental state, this examination may omit the genital and rectal examinations.)
- 4. performing a neurological examination to detect signs of central nervous system disorder.
 - 5. maintaining accurate records of examination results.

Whether screening is based on complete examinations or on the SB 929 screening algorithm, the job description of the nurse practitioner or physician assistant should also include:

- 1. reviews the patient's clinical record at the mental health facility, documenting any known physical complaints, disorders, or diseases and all medications taken by the patient.
- 2. discusses each patient with the consulting internist, and points out the patient's symptoms, physical findings, mental status findings, and psychiatric diagnosis.

Mounting a Mobile Medical Screening Program

In certain circumstances, the county mental health department may wish to create a mobile screening program. A mobile medical evaluation team staffed by physician's assistants or nurse practitioners can mitigate problems that discourage

screening. These problems include lack of space, physicians' lack of interest in medical screening, and too few new patient visits to justify hiring screening personnel for each program. The mobile screening team can use as its examination space a motor home converted into a medical screening facility²⁹ (Appendix B).

In addition to a motor home's usual features, a mobile medical van requires a copying machine, a computer and printer for word processing and record storage files. A motor home is easily converted into a mobile medical van by converting the bedroom into an examining office and the dining area into clerical space.

If the screening program uses a mobile medical van whose staff includes a medical clerk²⁹ (Appendix B), the nurse practitioner's or physician's assistant's job description should also include:

- 1. shares responsibility with the medical clerk for doing all maintenance chores for the mobile van (including interior and exterior structure, equipment and supplies).
- 2. shares responsibility with the medical clerk for driving the mobile van to and from the mental health facilities.
- 3. maintains good relationships with the staff at all mental health screening sites.
- 4. coordinates the medical screening program with the mental health facilities' mental health programs.

WHO SHOULD SCREEN: QUALIFICATIONS FOR CLERICAL STAFF

The job description of the medical clerk who is responsible for the clerical aspects of the screening program should include:

- 1. assists in obtaining the patient's signature on a Release of Information form.
- 2. prepares a packet of data collection forms for each patient, places the packet in a binder and gives the binder to the clinical staff.
- 3. ensures that all patient data forms are in the patient's clinical record.
- 4. obtains screening laboratory results from the local or central contract laboratory and notifies the clinical staff.
 - 5. submits laboratory test billings to third party payers.
- 6. reorders laboratory supplies from the contract laboratory well in advance of need.
- 7. prepares and types letters from the clinical staff to referral physicians and to patients' private physicians.
- 8. maintains a filing system for the screening program's records.

If the screening program uses a mobile medical van²⁹
(Appendix B), the job description of the medical clerk should include in addition:

1. shares responsibility with the nurse practitioner or physician's assistant for doing all maintenance chores for the

mobile van (including interior and exterior structure, equipment and supplies).

- 2. shares responsibility with the nurse practitioner or physician's assistant for driving the mobile van to and from the mental health facilities.
- 3. notifies the contract laboratory regarding times and places for pick-up of laboratory specimens or arranges for shipment of specimens to the laboratory.
- 4. maintains good relationships with the staff at all screening sites.
- 5. coordinates the medical screening program with the mental health program at the mental health facilities to be visited, including scheduling the times of the van's visits to the mental health facilities.
- 6. writes thank you letters to mental health facility staff who have been particularly helpful in coordinating the screening program with the mental health program.
- 7. if the medical clerk is a woman, she should act as a chaperon when a male physician's assistant or nurse practitioner carries out the physical examination of a female patient.

WHO SHOULD SCREEN: QUALIFICATIONS OF A MEDICAL CONSULTANT

The medical consultant reviews the results of laboratory tests and other medical data to help decide whether or not to refer patients for a complete evaluation of suspected physical disease. The consultant will help the staff differentiate between abnormal laboratory results that are probably false positive results and those that deserve further investigation. Usually, this consultation can be carried out by telephone.

If the screening program includes a complete physical examination by a physician's assistant or a nurse practitioner, the consultant should check the clinical staff's physical findings periodically in order to evaluate their skills and help them remain competent.

When a screening program is initiated in a facility that has psychiatric staff, a psychiatrist may feel competent to serve as the medical consultant. However, referral decisions can be difficult, and the psychiatrist may prefer that an internist or family physician make these decisions. In this case, and in facilities that do not employ psychiatrists, the facility should develop a contractual arrangement with a consulting physician.

The reviewing physician should decide which of the screening laboratory tests (included in the SB 929 algorithm or ordered as part of a complete examination) are clinically indicated by the patient's medical history or physical findings (as recorded on the Standard Medical History Form, Standard

Physical Examination Record, or Medical History Checklist). All clinically indicated laboratory tests are billable to the patient's third party payer. Submitting these bills and tracking collection will reduce the county's cost for the screening program. The screening program's nurse practitioner or physician's assistant should convey to the medical clerk which tests are billable. The medical clerk submits the bills to third party payers. When the screening program utilizes a contract laboratory, the laboratory can bill third party payers for the clinically indicated tests.

The psychiatrist or medical consultant must be interested in working with nurse practitioners and physician's assistants, comfortable with psychiatric patients, and knowledgeable about the relationships between physical diseases and psychiatric symptoms. 18.26.34

COSTS OF SCREENING: FISCAL ASPECTS OF A SCREENING PROGRAM

In settings in which medical evaluation is already in place, improving the quality of these evaluations by the methods suggested in this Manual need not increase evaluation costs. In fact, a more thorough approach to medical evaluation will be more cost-effective as measured by the cost-per-case-detected⁴⁸ (Appendix B).

New screening programs will incur additional costs for staff, supplies and perhaps for space. Plans for a new screening program should identify the funding source. In order to obtain incremental funding, county mental health departments and the State Department of Mental Health may have to convince the Legislature of the value of screening for physical disease. This Manual and the previous reports from the SB 929 Study^{30,31} can help in these efforts. Citizens' groups, such as the California Alliance for the Mentally Ill, and professional organizations, such as the California Medical Association and the California Psychiatric Association, can also be persuasive.

The costs of a screening program to the state and to the counties can be reduced in several ways, at least in 1991. First, in mental health programs other than 24-hour hospitals and the state hospitals, clinically indicated laboratory tests can be billed to the patient's third party payer (see pp. 41-42). For Medi-Cal, Medicare and private insurance patients, billing for clinically indicated tests will bring the county mental health

program considerable cost savings. Only for uninsured patients will the mental health program need to use state or local mental health funds to pay for all laboratory test costs.

Second, the costs of screening can be reduced by billing third party payers for the further medical evaluations of patients referred through application of the medical screening algorithm. These costs are billable to third party payers regardless of whether or not new physical disease is uncovered.

Third, because the screening program will order a large volume of a standardized panel of laboratory tests, the county mental health department should be able to negotiate a volume discount in the price charged by outside laboratories for this test panel.

Finally, the SB 929 Study found that screening patients for physical disease did not appear to increase the state's combined costs for medical and mental health care in the year after screening compared to the year before screening.³¹

COSTS OF SCREENING: CONTRACTING WITH A LABORATORY SERVICE

The screening program will need a formal arrangement with a clinical laboratory to do blood and urine tests. The formal, written agreement should spell out:

- 1. which laboratory tests that will be done routinely.
- 2. whether the laboratory will provide courier service for blood samples. If the laboratory does provide courier service, the frequency of sample pick-up should be specified (e.g., daily or "will-call").
- 3. the elapsed time between submitting a blood sample and the receving a report from the laboratory. The turn around time for routine laboratory tests should not exceed 24 hours.
- 4. how the laboratory will be paid (e.g., by purchase order, with or without a funding cap).
 - 5. the starting and ending dates of the arrangement.
- 6. who will bill third parties for billable laboratory tests.
- 7. whom to contact for answers to clinical or administrative questions.
- 8. how to access to test results 24 hours a day, 365 days a year.

The SB 929 Study used a national firm that picked up blood samples at the study's screening sites daily, provided all materials needed to draw, collect and prepare samples (including a centrifuge), provided reports within 24 hours of picking up the

samples, and billed third parties. The firm could install teleprinters at each study site to report test results. The firm gave the study team a reduced rate for the study's panel of laboratory tests because a standard panel was to be ordered in large volume. County mental health screening programs would order a standard panel in even larger volumes than did the SB 929 Study and should negotiate favorable prices for tests that cannot be billed to third party payers.

County mental health programs that wish to discuss contracting with a large, multi-site laboratory firm that can offer the services described above may contact:

1. Met West

Attn: Mr. Michael Hughes or Mr. James Pitton 18408 Oxnard Street

Tarzana, CA 91356

Telephone: 818/996-7300 or 1-800/339-4299

This firm worked with the SB 929 Study team.

2. SmithKline Beecham Clinical Laboratories
Attn: Mr. C. Mitch Morrow (for Northern California)

6511 Golden Gate Drive

Dublin, CA 94568

Telephone: 415/828-2500 or: 1-800/228-3008

Attn: Ms. Anna Hutchison (for Southern California)

15243 Vanowen Street

Van Nuys, CA 91405

Telephone: 818/786-3180

3. Roche Biomedical Laboratories

Attn: Mr. Louis Tzoumbas

383 E. Grand, Suite B

South San Francisco, CA 94080

Telephone: 415/871-4720

This firm has contracts with San Mateo, San Francisco, Alameda and Contra Costa Counties.

Sample test ordering forms produced by these firms are included in Appendix A.

CLUES SUGGESTING THAT THE MENTAL SYMPTOMS HAVE AN ORGANIC CAUSE

A number of findings should make the clinician suspect that an underlying physical disease is causing the signs and symptoms of the patient's "mental" disorder. These clues include²⁴ (Appendix B):

- 1. The mental disorder is a first episode.
- 2. The mental symptoms occur in a patient who is:
 - a. aged 40 or more
 - b. currently ill with a major medical illness
 - c. taking prescribed or over-the-counter medications that can cause mental symptoms
 - d. experiencing neurological symptoms: unilateral weakness, numbness, paresthesias, clumsiness, gait problems, headaches of increasing severity, vertigo, visual symptoms, speech or memory difficulties, loss of consciousness, or emotional lability.
 - e. experiencing weight loss (10% or more of base line weight), unusual diet (e.g., complete vegetarianism) or self-neglect that could cause vitamin-B deficiencies.
 - f. not experiencing serious life stress.
- 3. The patient has a past history of:
 - a. a physical illness that can impair organ function (neurologic, endocrine, renal, hepatic, cardiac, or pulmonary)

- b. recent falls or head trauma with unconsciousness
- c. alcohol or drug abuse
- d. taking several over-the-counter drugs.
- 4. The patient has a family history of:
 - a. inheritable metabolic disease (diabetes, porphyria)
 - b. degenerative or inheritable brain disease.
- 5. Certain mental signs are present:
 - a. altered level of consciousness
 - b. fluctuating mental status
 - c. any cognitive impairment
 - d. visual, tactile or olfactory hallucinations
 - e. episodic, recurrent, or cyclical symptoms interspersed with periods of being well.
- 6. Certain physical signs are present:
 - a. signs of major organ impairment e.g. ascites, edema
 - b. any focal neurologic deficit
 - c. diffuse subcortical dysfunction, e.g., slowed speech, mentation or movement; dysarthria; ataxia; incoordination; tremor; chorea; asterixis
 - d. cortical dysfunction, e.g., dysphasia, apraxia, agnosia, visuospatial deficits, defective cortical sensation.
- 7. Response to appropriate psychiatric treatment is poor.

 (Rethink the diagnosis, reexamine the patient, and consider seeking the advice of a consultant.)

REFERENCES

- 1. Barnes RF, Mason JC, Greer C, Ray FT: Medical Illness in Chronic Psychiatric Outpatients, Gen Hosp Psychiatry, 1983, 5:191-195
- 2. Beresford TP, Hall RCW, Wilson FC, Blow F: Clinical Laboratory Data in Psychiatric Outpatients, <u>Psychosomatics</u> 1985, 26:731-744
- 3. Brugha TS, Wing JK, Smith BL: Physical Health of the Long-Term Mentally Ill in the Community: Is there Unmet Need?, <u>Br J Psychiatry</u> 1989, 155:777-781
- 4. Burke AW: Physical Disorder Among Day Hospital Patients, <u>Br J Psychiatry</u> 1978, 133:22-27
- 5. Busch KA, Cavanaugh JL: Physical Examination of Psychiatric Outpatients: Medical and Legal Issues, <u>Hosp Commun Psychiatry</u> 1985, 36:958-961
- 6. Carlson RJ, Nayar N, Suh M: Physical Disorders Among Emergency Psychiatric Patients, <u>Can J Psychiatry</u> 1981, 26:65-67.
- 7. Chandler JD, Gerndt JE: The Role of the Medical Evaluation in Psychiatric Inpatients, <u>Psychosomatics</u> 1988, 29:410-416
- 8. Colgan J, Philpot M: The Routine Use of Investigations in Elderly Psychiatric Patients, Age, Ageing 1985, 14:163-167
- 9. Eastwood MR, Mindham RHS, Tennent TG: The Physical Status of Psychiatric Emergencies, Br J Psychiatry 1970, 116:545-550
- 10. Eilenberg MD, Whatmore MB: Physical Disease and Psychiatric Emergencies, Comp Psychiatry 1961, 2:358-363
- 11. Farmer S: Medical Problems of Chronic Patients in a Community Support Program, Hosp Commun Psychiatry 1987, 38:745-749
- 12. Faulkner LR, Bloom JD, Bray JD, Maricle R: Medical Services in Community Mental Health Programs, <u>Hosp Commun Psychiatry</u> 1986, 37:10 45-1047
- 13. Ferguson B, Dudleston K: Detection of Physical Disorder in Newly Admitted Psychiatric Patients, <u>Acta Psychiatr Scand</u> 1986, 74:485-489
- 14. Fitzgerald FT: Physical Diagnosis Versus Modern Technology: A Review, West J Med 1990, 152:377-382
- 15. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State,' A Practical Method for Grading the Cognitive State of Patients for the Clinician, <u>J Psychiatr Res</u> 1975, 12:189-198

- 16. Forsythe RJ, Ilk CR, Bard J, Wolford JA: Primary Medical Care in Psychiatry, <u>Current Psychiatric Therapies</u>, 1977, 17:91-97
- 17. Gjesdal K, Stromme JH: Multiphasic Screening Pgrogramme for Somatic Diseases Among Elderly Long-Term Psychiatric Patients, <u>Br J Psychiatry</u> 1974, 124:564-572
- 18. Hales RE, Yudofsky SC: <u>The American Psychiatric Press Textbook of Neuropsychiatry</u>, American Psychiatric Press, Inc., Washington, DC, 1987
- 19. Hall RCW, Gardner ER, Stickney SK, LeCann AF, Popkin MK: Physical Illness Manifesting as Psychiatric Disease, <u>Arch Gen Psychiatry</u>, 1980, 37:989-995
- 20. Hall RCW, Gardner ER, Popkin MK, LeCann AF, Stickney SK: Unrecognized Physical Illness Prompting Psychiatric Admission: A Prospective Study, Am J Psychiatry, 1981, 138:629-635
- 21. Hall RCW, Popkin MK, Devaul RA, Faillace LA, Stickney SK: Physical Illness Presenting as Psychiatric Disease, <u>Arch Gen Psychiatry</u>, 1978, 35:1315-1320
- 22. Handel M: Deferred Pelvic Examination: A Purposeful Omission in the Care of Mentally Ill Women, <u>Hosp Commun Psychiatry</u> 1985, 36:1070-1074
- 23. Herridge CF: Physical Disorders in Psychiatric Illness, <u>Lancet</u>, 1960, 2:949-951
- 24. Hoffman RS and Koran LM: Detecting physical illness in patients with mental disorders, <u>Psychosomatics</u>, 1984, 25:654-660
- 25. Honig A, Pop P, Tan ES, Philipsen H, Romme MAJ: Physical Illness in Chronic Psychiatric Patients from a Community Psychiatric Unit: The Implications for Daily Practice, Br J Psychiatry 1989, 155:58-64
- 26. Jefferson JW, Marshall JR: <u>Neuropsychiatric Features of Medical Disorders</u>, Plenum, New York, 1981
- 27. Johnson DAW: The Evaluation of Routine Physical Examination in Psychiatric Cases, <u>Practitioner</u>, 1968, 200:686-691
- 28. Kolman PBR: The Value of Laboratory Investigations of Elderly Psychiatric Patients, <u>J Clin Psychiatry</u> 1984, 45:112-116
- 29. Koran LM, Sox HC, Marton KI, Moltzen S: Mobile medical screening teams for public programs, <u>Hosp Community Psychiatry</u>, 1984, 35:1151-1152

- 30. Koran LM, Sox HC, Marton KI: A Medical Evaluation Study of Mental Health Service Clients: State Contract #82-73009 A-1, Final Report, Sacramento, 1984
- 31. Koran LM: The Cost Effect of Screening for Physical Disease in California's Public Mental Health Care System: A Report from the California Medical Evaluation Study to the Legislature in Response to Chapter 208, Statutes of 1982, Contract # 85-76249 A-1, Sacramento, California, 1987
- 32. Koran LM, Sox HC, Marton KI, Moltzen S, Sox CH, Kraemer HC, Imai K, Kelsey, TG, Rose TG, Levin LC, Chandra S: Medical Evaluation of Psychiatric Patients: I. Results in a State Mental Health System, <a href="https://doi.org/10.2016/nc.
- 33. Koranyi EK: Morbidity and Rate of Undiagnosed Physical Illnesses in a Psychiatric Clinic Population, <u>Arch Gen Psychiatry</u>, 1979, 36:414-419
- 34. Lishman WA: Organic Psychiatry: The Psychological Consequences of Cerebral Disorder, Second Edition, Blackwell, Oxford, England, 1987
- 35. Maguire GP and Granville-Grossman KL: Physical Illness in Psychiatric Patients, <u>Br J Psychiatry</u> 1968, 114:1365-1369
- 36. Maricle RA, Hoffman WF, Bloom JD, Faulkner LR, Keepers GA: The Prevalence and Significance of Medical Illness Among Chronically Mentally Ill Outpatients, Commun Ment Health J 1987, 23:81-90
- 37. Marks E and Broskowski A: Community Mental Health and Organized Health Care Linkages, in Broskowski A, Marks E, and Budman SH (eds): Linking Health and Mental Health, Sage Annual Reviews of Community Mental Health, Vol 2, Sage Publications, Beverly Hills, CA, 1981
- 38. Marshall HES: Incidence of Physical Disorders Among Psychiatric In-Patients, <u>Br Med J</u>, 1949, 2:468-470
- 39. Muecke LN and Krueger DW: Physical Findings in a Psychiatric Outpatient Clinic, Am J Psychiatry, 1981, 138:1241-1242
- 40. Murphy JM, Berwick DM, Weinstein MC, Borus JF, Budman SH, Klerman JL: Performance of Screening and Diagnostic Tests, <u>Arch Gen Psychiatry</u> 1987, 44:550-555
- 41. Roca R, Breakey WR, Fischer PJ: Medical Care of Chronic Psychiatric Outpatients, Hosp Commun Psychiatry 1987, 38:741-745
- 42. Rogan WJ, Gladen B: Estimating Prevalence from the Results of a Screening Test, Am J Epidemiol 1978, 107:71-76

- 43. Shatin L, Kymissis P, Brown W: Clinical Laboratory Abnormalities and Their Follow-up in a Mental Hygiene Clinic, Br J Psychiatry 1978, 133:150-155
- 44. Sheline Y: High Prevalence of Physical Illness in a Geriatric Psychiatric Inpatient Population, <u>Gen Hosp Psychiatry</u> 1990, 12:396-400
- 45. Snaith RP and Jacobson S: The Observation Ward and the Psychiatric Emergency, <u>Br J Psychiatry</u> 1965, 111:18-26
- 46. Sox HC: Quality of Patient Care by Nurse Practitioners and Physician's Assistants: a Ten-Year Perspective, <u>Ann Int Med</u> 1979, 91:459-468
- 47. Sox HC: Probability Theory in the Use of Diagnostic Tests: An Introduction to Critical Study of the Literature, <u>Ann Int Med</u> 1986, 104:60-66
- 48. Sox HC, Koran LM, Sox CH, Marton KI, Dugger F, Smith T: A Medical Algorithm for Detecting Physical Disease in Psychiatric Patients, Hosp Commun Psychiatry 1989, 40:1270-1276
- 49. Thomas CJ: The Use of Screening Investigations in Psychiatry, Br J Psychiatry 1979, 135:67-72
- 50. Wasson JH, Sox HC, Neff RK, et al: Clinical prediction rules: applications and methodologic standards. NEJM 1985, 313:793-799
- 51. White AJ, Barraclough B: Benefits and Problems of Routine Laboratory Investigations in Adult Psychiatric Admissions, Br J Psychiatry 1989, 155:65-72
- 52. White AJ, Barraclough B: Thyroid Disease and Mental Illness: A Study of Thyroid Disease in Psychiatric Admissions, <u>J Psychosom Res</u> 1988, 32:99-106
- 53. Wynne-Davies D: Physical Illness in Psychiatric Out-Patients, Br J Psychiatry 1965, 111:27-33

TABLE 1
STUDIES OF PHYSICAL DISEASE IN MENTALLY ILL PATIENTS: A SUMMARY

	Number of <u>Patients</u>	Rate of Physical Disease (%)	Newly dx Physical <u>Disease (%)</u>	Causal or Related <u>(制</u> "	Causal (%)
<u>Outpatient</u>					
Wynne-Davies 1965	36	32		16 (careful review)	
Forsythe 1977	677 outpt 433 inpt	56	29		
Hall 1978	658		4	9	
Koranyi 1979	2090	43	20	32	8.3
Muencke 1981	910		20		0
Barnes 1983	147	26	13		<1
Farmer 1987	59		53		
Maricle 1987	43	79	51	22.1***	3.5***
Honig 1989	156	53	32		

STUDIES OF PHYSICAL DISEASE IN MENTALLY ILL PATIENTS: A SUMMARY (CONT.)

	Number of <u>Patients</u>	Rate of Physical <u>Disease (%)</u>	Newly dx Physical <u>Disease (%)</u>	Causal or Related (%)"	Causal
Inpatient					
Marshall 1949	175	4 4	3	22	
Herridge 1960	209	50		26	5
Eilenberg 1961	1259	18			7.2
Snaith 1965	428	15		8	
Maguire 1968	200	24	17		
Johnson 1968	250			12	
Hall 1980/81	100	80	80	46	- -
Chandler 1988	224	77			
Sheline 1990	95	92			

STUDIES OF PHYSICAL DISEASE IN MENTALLY ILL PATIENTS: A SUMMARY (CONT.)

	Number of <u>Patients</u>	Rate of Physical <u>Disease (%)</u>	Newly dx Physical <u>Disease (%)</u> °	Causal or Related (%)	Causal
Emergency					
Eastwood 1970	100	40	16		1
Carlson 1981	2000			4.6	
Day Treatment					
Burke 1978	133	50	30		~
Roca 1987	42	93	46***		
Brugha 1989	121	41	5.8	~ -	

^{*} Disease detected by screening during treatment in the mental health program.

[&]quot;Physical diseases judged by the investigators to be causing or exacerbating a patient's patient's mental disorder.

[&]quot;Percent of diseases. Other percentages in this table are percentages of patients.

· 1,-1,000,000,000,000 1,001 10					<u> </u>	
Date of Report:			.			
Date Dictated:			-			
Date Typed:			·			·
General:	Temp.	Pulse	Respiration:	Blood Pressure	Height	Weight
Age: General Descripti					• • •	
	SKIN					"
Moisture Texture	Pigment Eruption	Hair Tattoos				
Natis Nodules	Bruises Scars	Ecchymoses Petechia:				
	EYES		•			
Lid-lag	Nystagmus	Exaphthalmos Conjunctiva				
Sciera Pupil	Acuity Movement	Ptosis				
Fields	Ophthalmyoscopic		-	4		
Designa	EARS	Acuity				
Drums Hearing	Discharge Mastord					
	NOSE					
Airways Sinus Tenderness	Septum	Mucosa				
Siller Terroterress	MOUTH		1			
Bresth	MOUTH Gums	Palate				
Lip Salivary ducts	Tangue	Teeth				
331114117 00213			-			
Tonsils	THROAT Exudate	Pharynx				
			-			
Stiffness	HEAD - NECK Thyroid	Trachea				
Masses	Vessels Symmetry	Bruit				
Shape ————————	24mmetra		+			
Cervical	LYMPH NODES	Occipital	,			
Epitrochlear	Axillary	Supraclavicular				
	CHEST		1			
Shape	Respiration	Symmetry	_			
	BREAST	_				
Masses Tenderness	Nioples	Discharge				
	HEART		7			
Apex	Phythm	Sounds M1				
Thrill Gallop	Murmurs Visual Pulsation	A2 P2				
Rate	Friction	Third			•	
Fremitus Adventitious Soun	LUNGS Breath Sounds ds	Percussion				
	BLOOD VESSEL					
Pulses	Vesset	Equality ,				
(C	ontinued on Reverse	Sidel		****		
			PAGE 1 of 3			
	PHYSICAL E	XAMINATION	1 1,000 1 01 5			
	☐ Admission	☐ Annua	ol .			
	Other		-			
	Confidential Clien	t/Patient Information	778	•	•	
MH 5731 (Revised	See Welfare & Institu	tions Code Section 5	348	ender e wiser in the company		

MH 5731 (Revised 6/86) CRDM Conference 2430

STANDARD MEDICAL HISTORY FORM

Patient Name	Date
Age Date of birth	Occupation
Home Address	
City	Telephone Number
MR#	

We are asking the questions below to find out if you have had any very bothersome physical problems in the last two months. Please circle the number for any symptom that has been very noticeable or worrisome to you. For each group of symptoms, please circle the number for "none of the above" if none of these symptoms has troubled you. Please do not circle any symptom number if the symptom has been minor or very mild.

HAVE YOU HAD ANY OF THESE SYMPTOMS IN THE PAST TWO MONTHS?

General symptoms:

FOR OFFICE USE

- 1 severe loss of appetite
- 2 unusual hunger
- 3 loss of more than ten pounds without trying
- 4 excessive thirst
- 5 fever over 100 degrees for more than a day
- 6 night sweats
- 7 difficulty tolerating hot or cold weather
- 8 a change in the way you sleep
- 9 none of the above

Problems with your head:

Have you had any of these in the past TWO MONTHS?

- 11 unusually severe or different headaches
- 12 headaches that wake you from sleep
- 13 headaches associated with vomiting
- 14 none of the above

HAVE YOU HAD ANY OF THESE SYMPTOMS IN THE PAST TWO MONTHS?

Problems with your eyes:

FOR OFFICE USE

- 15 pain in your eyes
- 16 a sudden need for new glasses
- 17 seeing double
- 18 loss of part of your vision
- 19 seeing flashing lights or forms
- 20 things becoming small
- 21 none of the above

Problems with your nose:

- 22 nose bleeds that start by themselves
- 23 stuffiness in your nose almost every day
- 24 unusual smells
- 25 none of the above

Problems with your mouth:

- 26 soreness in your mouth, lips, gums, or tongue
- 27 bleeding gums
- 28 strange tastes from familiar foods
- 29 none of the above

Problems with your throat:

- 30 a hoarse voice that did not get better
- 31 trouble swallowing food
- 32 none of the above

Problems with your ears:

- 33 ringing in your ears
- 34 a sudden change in your hearing
- 36 none of the above

Unusual lumps:

- 37 swollen glands in your neck, under your arms, or in your groin
- 38 lumps in your breasts
- 40 none of the above

HAVE YOU HAD ANY OF THESE SYMPTOMS IN THE PAST TWO MONTHS?

Skin problems:

FOR OFFICE USE

- 41 unusually itchy skin
- 42 unusually easy bruising
- 43 skin rashes
- 44 rapid loss of hair
- 45 unusual dryness of your skin
- 46 hair that has become coarse or brittle
- 47 hair that has become fine and silky
- 48 skin burning easily with sun exposure
- 49 a change in skin color or tanning
- 50 none of the above

Problems in your chest:

- 51 coughing that would not go away
- 52 coughing up blood
- 53 shortness of breath while walking or upon awakening at night
- 54 pain in your chest when resting
- 55 chest pain when you walk fast or uphill
- 56 very fast or irregular heart beat (palpitations)
- 57 a lightheaded feeling when you stand up
- 58 cramps in your legs during walking
- 59 swelling of your ankles or feet
- 60 none of the above

Problems with digestion or bowels:

- 61 persistent heartburn
- 62 swelling in your abdomen
- 63 abdominal pain for more than one day
- 64 a change in your bowel movements (size, shape or frequency)
- 65 vomiting for more than one day
- 66 black or bloody stools
- 67 getting full quickly while eating
- 68 none of the above

Trouble with urination:

- 69 decreased frequency or amount of urination
- 70 difficulty stopping or starting urination
- 71 blood or pus in your urine
- 72 burning when you urinate
- 73 getting up more than once
 - each night to urinate
- 74 loss of control of urine or stool75 pain or swelling in the testicles
- 76 none of the above

HAVE YOU HAD ANY OF THESE SYMPTOMS IN THE PAST TWO MONTHS?

Problems with joints or back:

FOR OFFICE USE

- 77 hot, painful or swellen joints
- 78 pain in your back that was so bad that you had to stay in bed
- 79 none of the above

Exposure to toxic chemicals in the past TWO MONTHS:

- 80 toxic chemicals/fumes at work
- 81 toxic chemicals/fumes in your hobbies
- 82 toxic chemicals/pesticides in your garden
- 83 radioactive substances (exposure ever)
- 84 none of the above

Problems with your nervous system:

- 85 fainting spells
- 86 a lot of trouble with thinking or speech for brief periods
- 87 convulsions or fits
- 88 weakness in your arms or legs
- 89 a loss of coordination
 - bumping into things frequently
- 90 numbness or tingling in your body
- 91 shaking that you could not control
- 92 difficulty with speaking
- 93 a change in your handwriting
- 94 repeated muscle cramps
- 95 recent head injury
- 96 none of the above

Habits

98	-	Drink	coffee?	Yes	ИО	Ιf	yes,	how	many	packs/day?
99	-	Drink	alcohol?	Yes	No	Ιf	yes,	how	many	oz./day?
100	-	Drink	wine?	Yes	No	Ιf	yes,	how	many	glasses/day?
101	-	Drink	beer?	Yes	No	Ιf	yes,	how	many	oz./day?

------NEXT QUESTION FOR WOMEN ONLY-----

Problems with menstruation:

- 102 a sudden change in your menstrual periods
 (discomfort, regularity, or amount of flow)
- 103 bleeding or spotting between your periods
- 104 excessive bleeding with your periods
- 105 none of the above

PAST HISTORY

Have you had any of these illnesses? (Circle the number for any illness that you have had)

106 - Asthma 107 - Bladder Infection 108 - Cancer 109 - Diabetes 110 - Emphysema 111 - Fits/Convulsions/Epilepsy 112 - Gallstones 113 - Glaucoma 114 - Gout 115 - Heart Attack 116 - Hepatitis 117 - High Blood Pressure 130 - Others	119 120 121 122 123 124 125 126 127 128		Jaundice Kidney Infection Kidney Stone Liver disease Meningitis Pneumonia Rheumatic Fever Syphilis Thyroid disease Tuberculosis Ulcers Venereal disease
List any diseases that have required hospita	1 +	a a t	ment
Disc dily diseases that have required hosbita	Yes		
131 -			
			
List any operations you have had:	<u>Ye</u>	2.5	
132 -			
			ton plate the same of the same
List any serious injuries vou have had:			
133 -			
List any serious allergies vou have to foods			licines:
Drug or Food Describe Re	actio	חכ	
134			
			·

If you	If you have a regular physician, what is his or her:						
135 -	Name: Address: Telephone						
Medic	ines you h	ave taken	in the past	t month			
pills	, vitamins	eck the app , and aspin scription	rin product	s if you	w. Include use them of t:	birth cont ften. Give	rol the
		SOUR	CE	FREQU	JENCY OF US	<u> 3E</u>	
Drug or Medicine (Name)		Pre- scribed by M.D.	Not pre- scribed. Over the counter	Take Dail		ast Less	k
							- -
			· · · · · · · · · · · · · · · · · · ·				_
							-
			Y MEDICAL 1				
		e has had t conditio		following	g condition	ns, circle	the
138 - 139 - 140 - 141 - 142 - 143 -	Senility Schizophr Depressio	or Convuls or Dementi enia (diag: n (diagnos agnosed by	ions a nosed by a ed by a phy	146 - Por 147 - Alc 148 - Hur physician ysician)	coholism ntington's	Chorea	

MEDICAL HISTORY CHECKLIST

PATIENT NAME:		DATE		
MEDICAL RECORD NUMBER	₹:			
INTERVIEWER NAME:				
PLEASE CHECK "YES" OF	R "NO" FOR EACH OF THE FOLLOWI	NG CONDIT	IONS:	
Have you <u>EVER</u> had:			YES	<u>00</u>
Fit	ts, Convulsions or Epilepsy			
Emp	physema			
Dia	abetes			
Ast	thma			
Hic	gh Blood Pressure			
Thy	yroid Disease			
	IF ANY OF THE FOLLOWING SYMP' OME TO YOU; OTHERWISE, CHECK "		BEEN	VERY
In the past TWO MONTH	HS, have you noticed:		YES	NO
	Blood or pus in your urine		-	
	Pain in your chest when resti	ng		
In the past TWO MONT	HS, have you had:			
	Headaches associated with vom	iting		
	Loss of control of urine or stools (bowels)			

[Decision: R DNR]

SB 929 form

PHYSICAL EXAMINATION RECORD

PATIENT NAME	DATE
MEDICAL RECORD #	
VITAL SIGNS: BP: (Sit)mm Hg PUL TEMP:F°	SE:/min. (regIrreg)
GENERAL APPEARANCE:	MOUTH:
normal	normal
1 abnormal	20 abnormal
2 422	
SKIN:	NECK:
2 cyanosis	21 thyroid enlarged
3 rash	22 thyroid bruit
4 jaundice	23 thyroid nodule
5 spider angioma	24 other neck abnormality
6 other abnormality:	•
-	
HEAD:	LYMPH NODES:
normal	normal
7 abnormal:	25 enlarged
	26 abnormal:
EXTRAOCULAR MUSCLES:	
normal	BREASTS:
8 abnormal:	normal
	27 abnormal:
PUPILS:	28 not done
normal	
9 Argyl-Robertson pupil	THORAX:
<pre>10 other abnormality:</pre>	normal
	29 increased AP diameter
VISUAL FIELDS:	30 decreased breath sounds
normal	31 wheezes/prolonged expir.
11 abnormal	32 rales >=1/3 up lung fields
BURL TRA	33 other abnormalities:
EYELIDS:	HEART:
normal 12 lid lag	normal
13 lid retraction	34 abnormal:
14 other abnormality:	34 abitormar.
14 Other abnormaticy.	PERIPHERAL PULSES:
SCLERAE:	normal
normal	35 abnormal:
15 icteric	JJ GDIIGI.
16 other abnormality:	ABDOMEN:
to other aphormaticy.	normal
FUNDI:	36 liver enlarged
normal	37 ascites
17 abnormal:	38 other abnormalities:
TI GNIOTIMET.	TT TOILE WALLTINGTEGE.

SB 929 (orm

normal 18 abnormal:

NOSE:

normal 19 abnormal:

NEUROLOGICAL EXAMINATION

LEVEL OF CONSCIOUSNESS

normal

46 other abnormality:

CRANIAL NERVES

all cranial nerves normal 56 CN1 abnormal 57 CN2 abnormal 58 CN3 abnormal 59 CN4 abnormal 60 CN5 abnormal

SENSORY EXAMINATION

vibration sense normal 66 vibration sense decreased ____ position sense normal 67 position sense decreased Romberg test normal 68 Romberg test positive

MOTOR SYSTEM

gait normal

76 akathisia
77 resting tremor
78 intention tremor
78 bizarre gait
79 tic:
79 ataxic gait
78 bradykinesia
79 ther abnormaltities:
80 bradykinesia
81 asterixis
82 other abnormal involuntary movements:

EXTREMITIES & JOINTS:

normal 39 tremor 40 clubbing

41 other abnormalities:

SPINE:

normal 42 abnormal:

SPEECH

normal normal normal

43 diminished

44 hypervigilant

45 inattentive

normal

47 dysarthria

48 delayed answers

49 word-finding difficulty 50 word substitutions 51 disrupted grammar 52 nonsense syllables 53 perseveration 54 loose associations 55 other abnormalities:

61 CN6 abnormal

62 CN7 abnormal

63 CN8 abnormal

64 CN9,10 abnormal

65 CN 12 abnormal

movements:

```
normal upper extremity muscle strength
83 symmetric distal weakness
84 asymmetric distal weakness
85 symmetric proximal weakness
86 asymmetric proximal weakness
     normal lower extremity muscle strength
87 symmetric distal weakness
88 asymmetric distal weakness
89 symmetric proximal weakness
90 asymmetric proximal weakness
     upper extremity deep tendon reflexes
   all 1-2+ & symmetric
91 hyperactive and symmetric
92 hyperactive and asymmetric
93 bilaterally absent
94 unilaterally absent
95 abnormally slow relaxation phase
      lower extremity deep tendon reflexes
all 1-2+ and symmetric
96 hyperactive and symmetric
97 hyperactive and asymmetric
98 bilaterally absent
99 unilaterally absent
100 abnormally slow relaxation phase
    no pathologic reflexes
101 symmetric Babinski response
102 asymmetric Babinski response
103 glabellar reflex
     no cerebellar signs
104 finger-to-nose abnormal
105 abnormal RRAM
106 abnormal heel-to-shin
```

MEDICAL RECORD

DEFINED DATA BASE

PART I PATIENT PROFILE

The information requested on this form is solicited under authority of Title 38, United States Code, "Veterans' Benefits", and will be used to assist the doctors in evaluating your condition and other professionals in their efforts to help you or your family. It will not be used for any other purpose. Disclosure is voluntary. However, failure to furnish the information will result in our inability to promptly serve your needs. Failure to furnish this information will have no adverse effect on any other benefit to which you may be entitled.

INSTRUCTIONS: This form contains general information about the patient which will be collected upon entry to ANY LEVEL OF CARE. DATA OF PART I AND II WILL BE MOVED FORWARD TO CURRENT MEDICAL RECORD UPON READMISSION. Data should be reviewed before each readmission and new data added or corrected by dating the item response. IF MANY CHANGES ARE INVOLVED, A NEW SHEET SHOULD BE PREPARED. Use blank spaces to update data and give specific information. Be sure to use item no. to identify updated data. A. SOURCE OF INFORMATION Z. RELATIVE 3. FRIEND I. PATIENT 4. MEDICAL RECORD OTHER

5. (Specify) B. NEXT OF KIN Give relationship, name, address with zip code and phone number) C. DEMOGRAPHIC DATA 2. MARITAL STATUS 3. RELIGION I. RACE A. SINGLE B. MARRIED C. DIVORCED D. WIDOWED 4. MILITARY HISTORY 6. NO. OF PEOPLE IN HOUSEHOLD 5. LIVING ARRANGEMENTS (Check one box, add comments if appropriate) A. SPOUSE B. PARENTS C. RELATIVES D. FRIENDS E. ALONE F. INSTITUTION G. Specify 7. EMPLOYMENT (Check one box, complete information if appropriate) A. WORKING __ __ HOURS A WEEK D. STUDENT -E. RETIRED -B. SICK LEAVE-PAID C. UNEMPLOYED - HOW LONG?

DEFINED DATA BASE

PART !

PATIENT PROFILE

MEDICAL RECORD	DEFINED DATA BASE	PART I PATIENT PROFILE
8. HOUSING		
A. OWN HOME		
B. RENTED HOME		
C. APARTMENT	•	
D. RENTED ROOM		
E. MOBILE HOME		
HEALTH FACILITY F. (Specify)		
OTHER G. (Specify)		
H. NONE		
9. COMMUNITY		
A. URBAN	3. SUBURBAN	C. RURAL
10. EDUCATION (Highest grade completed)		
11. OCCUPATION		
12. INCOME /This information is needed to assi-	st the patient and his family during hospitalization and	upon discharge. There is no requirement for the
patient to answer this question if he does no	il wish (o do so.)	
A. PATIENT'S ESTIMATE OF ANNUAL INCOM	1E.	
B. APPROXIMATE MONTHLY INCOME FROM	FOLLOWING SOURCES:(I appropriate)	
(1) COMPENSATION		
(2) NSC PENSION		
(3) A & A OR HOUSEBOUND		
(4) SOCIAL SECURITY	٠٠٠	
(5) PUBLIC ASSISTANCE		
OTHER (6) (Specify)		
(7) NONE		
13. ADDITIONAL DATA		
SIGNATURE AND TITLE		DATE
-		
		•

MEDICAL RE	corp	DEFINED DATA	LAGE	PART II
			DAX	PATIENT PROFILE
	tions of Part I - Patient Pro		e dates.)	
•				
		•		
				
E SERVICE CONNECTED DISA	BILITIES (Specify or check none.	,	•	•
HONE	•			
C. FAMILY WEDICAL HISTORY	(For positives, indicate relations	hip.)		
1. DIA BETES	2. HEART DISEASE	1 HYPERTENSION	4. STROKE	S. KIDNEY DISEASE
S. CANCER	7. ARTHRITIS	8. THERCULOSIS	s. DRU GS	10. ALCOHOL
11. EPILEPSY	12. MENTAL ILLNESS (Specify)	13. OTHER		
D. MEDICATIONS (State those of	urrently used, dosage, and compli	ence.)		
		·		
HONE				
E OTHER ORUGS (State amount	and number of years used - when	anniicabia)		
1. ALCOHOL	, , , , , , , , , , , , , , , , , , , ,	3. DRUGS OTHER THA	N THOSE IN "O".	
Z. TOBACCO		4. NONE	•	
F. FOOD AND DRUG REACTION	S INCLUDING ALLERGIES.			
•				
				
			1	

PART II

PATIENT PROFILE

MEDICAL RECO	RD		DERNED DATA	BASE	PA'	PART II TIENT PROFILE
G. IMMUNIZATIONS (Check appropri	ere box and give der	e.)				
1. TETANUS	;	2 POL10	<u></u> мо		1. OTHER YES	NO
				·		
H. DIET						
1, KIND OF GIET FOLLOWED						
2 WMO PREPARES FOOD	,					
3. PROBLEMS WITH FOOD OR MEA	ı_S					
1. GLASSES	2 DENTURES		2. HEARING AIDS	4. BRACES/S	PLINTS .	ARTIFICIAL LIMBS
6. EATING AIDS	7. ORESS AND GROOMING A	10\$	8. OTHER (Describe)	9. HOHE		·• ·
J. HOBBIES/ RECREATIONAL INTE			9 (Specify)			
K. PATIENT'S LIFE STYLE (Descr	ibe a cypical day-in	ciudin e ele	ep cycle.)			
,						
L. PATIENTS CONCERNS (What are	they? Specify whed	her work, m	oney, veteran's banefits, heeld	h, diet, lamily, houser.	L erc.)	
M. PATIENT'S EXPECTATION OF	TREATMENT (II add	nutted, indi	care petients idea of langth of	etay, include knowled;	e of condition and e	stent of family involvement.)
SIGNATURE AND TITLE					DATE	
				}	<u>.</u>	

!

ME	חוכ	- Δ1	RECERT

DEFINED DATA BASE

PART IV SYSTEM REVIEW

INSTRUCTIONS: Check 'yes' or 'no' only when question is asked. Leave blank if question is not asked. Comment specifically if postive symptom. Identify bynumber. Upon readmission Part IV is moved forward with Parts I, II and VI to current admission record.

			A-GENERAL
	i	Ī	
YES	40	•	
		1 1	WEIGHTTMANGE .
		2	FEVERXR-CHILLS
	1	3	NIGHT-SPEATS
	Ī	4	POLYDRIA
		5	BL SEDING
	Ī	1 6	LUMPSTOR MASSES
	<u> </u>	7	VERTICE
		8	SYNCORE
		,	PRURITS
		ני ן	RASH
		111	CIA BETTS MELLITUS
		112	THYROm OISOROERS
	<u> </u>	13	CANCER
			B-EYE-EAR-NOSE-THROAT
	!	1	VISUAL CHANGE
	!	2	OIPLOPIA
	1	3	EYE PRIN
		4	HEARING LOSS
		5	TINN: *US
		`	EAR DISCHARGE
			EPISTARIS
			OBST#UCTION
			TEETH-DEN TURES
		-	BLEEDING GUMS
	!	' ,,	HOARSENESS
	,		C-BREASTS
		1	LUMPS
		2	PAIN OR TENDERNESS
		3	NIPPLE DISCHARGE
			D-MUSCULO SKELETAL
		-	BACKACHE
			JOINT PAIN
			STIFFNESS
		٠	JOINT SWELLING
		5	MUSCLE WEAKNESS

(Continue on reverse)

DEFINED DATA BASE

PART IV

SYSTEM REVIEW

MEDICAL RECORD			ECORD	DEFINED DATA BASE	PART IV SYSTEM REVIEW	
٤s	NO.	•		E-RESPIRATORY		
_		1	COUGH			
		2	SPU TUM			
		3	RHEUMATIC FEVER			
		4	PLEURISY			
		5	PHEUMONIA			
	i	6	TUBERCULOSIS			
		7	SHORTNESS OF BREATH			
		8	WHEEZING			
		9	ASTHMA			
		10	PULMONARY EMBOLUS			

	F - CARDIO VASCULAR	
_ '	HEART DISEASE	
2	HYPERTENSION	
3	RHEUMATIC FEVER	
4	CHEST PAIN DISCOMFORT	
5	SHORTNESS OF BREATH	
6	PAROXYSMAL NOCTURNAL DYSPNEA	
7	PALPITATIONS	
	MURMURS	
9	EDEMA	
10	CLAUDICATION	
11	THROMBOPHLE BITIS	

E5	NO	<u>.</u>		G-GASTROINTESTINAL
		1	DYSPH AGI A	
		2	HEARTBURN	
		1	NAUSEA & VOMITING	
		4	HEMATEMESIS	
		3	MELENA	
		6	ABOOMINAL PAIN	•
		7	JAUNOICE	
			FOOD INTOLERANCE	
			CHANGE BOWEL HABIT	
		10	HEPATITIS	
		11	PEPTIC ULCER	
Ī		12	PANCREATITIS	

.E2	40	•		H-GENITO URINARY	
\neg		1	FREQUENCY		
		2	NOCTURIA		
		3	DYSURIA		
\neg		•	INCONTINENCE		
\neg		5	DRIBBLING		
		•	POLYURIA		
		7	URINARY INFECTION		
\neg		•	STONES		
		,	VENEREAL DISEASE		
		10	DISCHARGE		
\neg		11	IMPO TENCE		
		12	A SHORMAL, MENSES		
		13	VAGINAL DISCHARGE		
		14	MENORRHAGIA		
		15	METRORRHAGIA		
T		16	DYSPAREUNIA		
		17	MENOPAUSE		
1		18	CONTRACEPTION		
_		19	PELVIC PAIN		

MEDICAL RECORD			DEFINED DATA BASE	PART IV SYSTEM REVIEW
25 NO	0		1-NEUROLOGIC	
	Ti-	SEIZURES		
		LOSS OF CONSCIOUSN	ESS	
	T	3 PARALYSIS		
	i	SENSORY CHANGE		
	ī	S TREMOR		
		GAIT DISTURBANCE		
		T HEADACHE		

ES	٧0	•	J-PSY CHIATRIC
\neg		1	MEMORY CHANGE
1		2	TROUBLE WITH DECISIONS
\neg		3	SLEEP DISTURBANCE
\neg		4	CRYING SPELLS
1		5	THOUGHTS OF SUICIDE
T		5	DIFFICULTY WITH WORK
7		,	FATIGUE
1		9	LOSS OF APPETITE
1		,	TROUBLE WITH SEX LIFE
7		10	SOCIAL WITHORAWAL
\neg		11	HALLUCINA TIONS
\neg		12	IMPROBABLE BELIEFS
T		13	ANXIETY
		14	DEPRESSION

SIGNATURE AND TITLE



1) De	partment of Veter	ens Affairs				
	MEDICAL RECORD		DEFINED DA	TA BASE	P	PART V PHYSICAL EXAMINATION
FIGHT	PRESENT WEIGHT	IDEAL WEIGHT	TEMPERATURE	PULSE	BLOOD PRESSURE	
GENERAL APPE	ARANCE	<u>, L.,,</u>		<u> </u>		
			A – SKII	<u> </u>		
			A - 3KII	•		
1, TURGOR 2. LESIONS						
2. LESIONS						
4. NAILS	·					
HEAD		8	EAD-EYES-EARS	-NOSE-THROAT		•
1. SKULL					•	
2. SCALP						
J. VISION /Spe	rcify test used)					
4 EXTRACCU	LAR MOVEMENTS					
S. EYELIOS						
6. CONJUNCT	IVAE					
7. CORNEA						
8. SCLERA						
9. LENS						
10, PUPILS						
FUNDI						
12. AUDITORY	ACUITY (Specify test used)					
EXTERNAL	EAR					
CANALS, DE	RUM					
NOSE						
15. EXTERNAL						
16, MUCOSA						
17. SEPTUM						
18. TURBINATE						
MOUTH-THROA! 19. LIPS	•					
19. LIPS 20. BREATH						
20. BREATH, GUI	MS					
21. TEETH, GO. 22. TONGUE						
23. MUCOSA						
24. TONSILS						
25. PHARYNX						
26. SPEECH						
27. SALIVARY	GLANOS					
			(Continue on re	W 67741		
			CONTINUE OR FE	* E' 1 E /		

DEFINED DATA BASE
PART V
PHYSICAL EXAMINATION

44 FORM 40 70700

MEDICAL RECORD	DEFINED DATA BASE	PART V PHYSICAL EXAMINATION
	C - NECK	
RANGE OF MOTION		
APPEARANCE		
TRACHEA		
THYROID		
MASSES		
	D - BREASTS	
. MASSES		
1. NIPPLES		
	E - NODES	
CERVICAL		
Z. AXILLARY		
3, INGUINAL		
	F - CHEST	
CONFIGURATION OF THORISA		
RESPIRATORY MOVEMENTS		
I. PERCUSSION		
I INSPIRATORY BREATH SOUNS		
S. EXPIRATORY BREATH SOUNDS		
	C VACCULAR (Annual Control Con	
	G - VASCULAR (dueram when applicable)	
CAROTIO PULSE		
. RADIAL PULSE	 	
FEMORAL PULSE	-	
POPLITEAL PULSE		
5. POSTERIOR TIBAL PULSE		
5. DORSAL PEDAL PULSE	 	
. NECK VEINS		
. PERIPHERAL VEINS		
	11 145AGT/Discount cuttacts, proceedings	
	H = HEART (Diagram sounds, murmurs, gallops)	
1, IMPULSE		
2. PALPATION		

3. RHYTHM 4. AUSCULTATION

MEDICAL RECORD	DEFINED DATA BASE	PART V PHYSICAL EXAMINATION
	I - ABDOMEN	
1. ABDOMINAL WALL		
2. DISTENTION		
J. TENDERNESS		
4. LIVER		
S. SPLEEN		
6. KIDNEYS	•	
7. OTHER MASSES		
8. BOWEL SOUNDS		
9. VENTRAL HERNIA		
	J - RECTAL	
1 AMUS AND CRUMCTER		
1. ANUS AND SPHINGTER		
2. RECTUM		
J. PROSTATE		· ·•
4. TEST FOR OCCULT BLOOD		
MALE	K = GENITALIA	
1. PENIS AND URETHRA		
Z. SCROTUM		
3. TESTES		
4. EPIDIOYMIS		
5. INGUINAL CANAL		
FEMALE		
6. EXTERNAL GENITALIA		
7. URETHRA		·
8. VAGINA		`
9. CERVIX		
IQ. UTERUS		
11. ADNEXA	•	
UPPER	L - EXTREMITIES	LOWER
1. MUSCLES		
2. JOINTS		
J. EDEMA		
4. AMBULATION		
S. COORDINATION		
S. AMPUTATION, DEFORMITIES		
	M - SPINE	
1. CONFIGURATION		

(Continue on reverse)

2. MOBILITY
3. TENDERNESS

	N - NEUROLOGICAL	
1. C. IAL NERVES 2. GAIT 1. BICEPS REFLEX 1. PRICEPS REFLEX 2. PATELLAR REFLEX 6. ACMILLES REFLEX 7. PLANTAR RESPONSE 8. PERIPHERAL NERVES 9. SENSORY	R L (g - 4 +1)	
	O - MENTAL STATUS	
1. ORIENTATION 2. MEMORY 3. MOOD INSCIOUSNESS		

EDICAL RECORD

ORAL MAXILLOFACIAL DEFINED DATA BASE

PART VI HISTORY

INSTRUCTION: To be completed by a dentist. Upon readmission Part VI is moved forward with Parts I, II, and IV to current admission records.

A. CHIEF COMPLAINT

B. HISTORY OF PRESENT ILLNESS

C. PAST HISTORY-Cleck yes or no only to those questions asked. Check nothing if question not asked. Use area at right to comment specifically regarding past history.

YES	но	
		1. FACIAL INJURIES
		Z DENTAL TREATMENT
		3. SWELLINGS OR INFECTIONS
		4. NUMBESS OR BURNING SENSATION
		5. BLEEDING PROBLEMS
		6. CHEWING OR SWALLOWING DIFFICULTY
		7. DEN TURES (Removable)
		8. LOCAL ANESTHESIA (Problem)
		9. ALLERGIES
		JO. BIOPSY
		11. SURGICAL PROCEDURES
		12 CANCER-TREATED

ORAL MAXILLOFACIAL

DEFINED DATA BASE

PART VI

M	FI	וכ	C.	Δ	L	R	E	C	0	R	D

ORAL MAXILLOFACIAL DEFINED DATA BASE

PART VI

D-CLINICAL EXAMINATION - Check normal (N) or abnormal (AB) only for those areas actually examined. Use blank space at right to commen specifically regarding abnormal findings.

		فسيرون ومرود والمستون والمراجع
FIND	INGS	
N	AB	
		1. FACIAL SYMMETRY
	L	2. SKIN
		3. GLANOS-NODES
		4 LIPS
		1
	;	5. BUCCAL MUCOSA
	 	6. ALVEDLAR RIDGES
	<u> </u>	7. FLOOR OF MOUTH
	<u> </u>	a. TONGUE
		9. PALATE
		10. ORO-PHARYNX
	!	11. GINGIVA
		12. ORAL HYGIENE
		13. OCCLUSION
		14. EXCESSIVE TOOTH MOBILITY
	<u> </u>	ITS, MANDIBULAR MOVEMENTS

									E - CH	IART								
LEGEND																		
0 - Caries Restarable 1 - Mon-Restarable					^		c	D	E	F	G	н	1	J				
X- Missing	1	1	2	3	4	5	6	7	8	9	10	1.1	12	13	14	15	16	٤
XXX - Replaced by denture. (3XX6) - Replaced by	J H T	32	31	30	29	28	27	28	25	24	23	22	21	20	19	t e	17	- F
bridge.					T	5	*	9	P		N	M	L	ĸ				
						F-R(DENTG	ENOG	RAMS									

1. PERIAPICAL (No.) 2. BITE-WING (No.) 3. OTHER (Specify, give no.) 4. PANDRAMIC (No.)

G. SIGNIFICANT LABORATORY AND RADIOGRAPHIC FINDINGS

MEDICAL RECORD

ORAL MAXILLOFACIAL DEFINED DATA BASE/INITIAL ASSESSMENT AND PLANS

PART VI

(DATE)

Use problem number, title, and separate headings for (1.) Assessment, (2.) Plans: DX 'Diagnostic', RX 'Therapeutic', Pt. Ed. 'Patient Education', DO NOT abbreviate problem titles. Continue on reverse if necessary.

IS PATIENT PHYSICALLY ABLE TO HAVE THE INDICATED DENTAL TREATMENT YES NO 2 ESTIMATED HOSP	TAL STAY REMAINING.	O HAVE YES HO	S PATIENT PHYSICALLY ABLE TO HAVE THE INDICATED DENTAL TREATMENT			

ISIGNATURE OF PHYSICIANI

Y					MEDICAL HIST	-				olete all inform	etion.	-	
,e Na	All	Medicare No	Delta i		Medicaid No.	Today s Di			irthdate		Male [
Last Name		<u> </u>	First		Miggle	Daytime Pt	none			Home Phone	1		
Address			City	·	State Zip	1	Mernel Str	itus		Occupation			
Person to notify in	emergency		·		Daytime Phone	Relati	onstrip			<u> </u>	Last Phy	ucal E	xem-nepon
·					Phone	Fame	y or Referrir	g Doctor			Phone No.		
By Doctor				Yes	What are your present medica								
May I Contact Either Doctors For Your P	ast Health F			No□	<u> </u>				a bassa	have be = ==		45 =	
Family History		IVING	Death	IF C	DECEASED	Any b				have had an			
		d Fair Poort	Age		Death Cause	1		Yes No	Relationship			No	Relationsh
Father					<u></u>	Asthma				Hay Fever		!	i I
Mother	 					Arthritis				Insanity		+	1
Brothers (Circle Sisters Sext	 					Allergies	3			Kidney Dis	sease)	1	1
1. M F						Anemia				Laukemia		<u> </u>	<u> </u>
2. M F						Alcohon	sm	-	<u> </u>	Migraine		1-	[
3. M F						Bleeding	Tend.		!	Nervous B	reak n	1	1
4. M F						Cancer			<u> </u>	Obesity		 	<u> </u>
5. M F						Colitis				Rheumatis	im		<u> </u>
Husband C Wife						Congeni	tai Heart			Rheumatic	Fever	-	ļ
Sons (Circle Daughters Sex)					JA R	Dupque				Stroke		1	ļ
1. M F					1 9 20	Proper	£ 4			Suicide		<u> </u>	
° M F						Soiter	N H			Stomach	Jicers		
M F						High BI	Press.	١, ١		Tubercuio	sis		
4. M F						Heart D	sease					!	
5. M F	11					1							
6. M F	 												
Do you Smoke	Yes 20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	BITS Daily (Consum	_ Pkgs. A _ Cups A _ oz. A _ oz. E	MEDICATIONS / If Taken / Antacids	Cortisone Cough M Digitalis Dilantin Hormone	inning Pills dedicine	90000	Laxatives Phenobard Shots Sleeping P Thyroid Me Tranquilize		Water Weight Other (Pills . Redu list) _	iang Pills
Operations yo	u have h	ad:	Yes		Diseases you have had equiring hospitalization		Ye	ar		liness not hospitalizati	on		Year
Orugs you are allergic to	:				Describe any serious injudicidents you have had	uries or							
Do you have ver Do you feel bloa Are you now on "ave you ever?"	ing regular ry heavy b ited and in of have y	ng between y leeding with ritable before ou ever takei arriage?	our perion your perion your perion the birt	ds? ods? riod? h control p	✓ Yes No	When? When? When?							
you ever h you regularly How many child How many stillb How many prem Date of last mer	y have the ren born a inths Nature birth	cancer test of	of the cer	vix?			last test _		MEN only: Loss of sex Treatment !	Have you evue activity? For genitals (primore penis?	ver had: or how long? vete perts)?		<u>.</u> .
How many misc	arriages . Irean oper:		<i></i>]	Hernia (rup)	rure)?			

How many miscarriages

STUDY OF SYSTEMS

Γ	Conditions	1	√ No		Conditions	1	No		Conditions	Ye	s No
	Fever	<u> </u>		Ī	Stiffness				is Your Life:		-
	Chills	1		NE	Swelling				Satisfactory		T
G	Bruise Easily			Ç	Lumos				Boring		\top
E	Swollen Glands			1	Other*				Demanding	1	1
Ĉ	Loss of Memory	<u> </u>			Appetite Poor				Unsatisfactory	T	T
	General Weakness	Ì		Ì	Indigestion/Heartburn				is There Worry Over:	-	
	Aches/Pains		<u> </u>	G	Nausea				Home Life	1	T
	Double Vision	I		A	Variting Blood			5	Marnage	Ī	T
	Light Flashes	Ī		R	Abdominal Pain or Cramps			CH	Job	Ī	Ī
	Blurred Vision w/o Glasses			N	Abdominal Tension			0	Children	!	
	Halos Around Lights			Ē	Diarrhea			00	Money	_	
	Eye Pains			Ī	Constipation			Ċ	Do You:		
H	Ear Pains	1		N A	Bowel Habit Changes			L	Often Feel Depressed		<u> </u>
Â	Ear Drainage			1	Rectum Blood Passage				Have Irrational Fears		
	Buzzing/Ringing in Ears	i .		7	Black Tar-Type Bowel Movements				Feel Upset		1
1	Nosebleeds		1	1	Otner*				Feel Things Often Go Wrong		
	Sinus Problems								Feel Shy		
	Swallowing Problems	į			Up Nights to Urinate				Cry Easily	j	1
	Deafness			×	Blooderatifie				Feel Interior		1
	Mouth, Tooth or Tongue Problemen			Ž,	Bitning of Fain Wale Unating				Have You:		
	Persistent Hoarseness		-	1	archiem Passing Urine				Attempted Suicide		1
1	Severe Headaches	, ii			Trouble Controlling Urine				Seriously Considered Suicide	- 1	
	Other*]	Other*				Lump in Testicles	1	
	Rash	Ī		Ī	Leg or Arm Weakiess	1		G E	Penis Discharge	-	
S K	Changing Moles	_c	5	, E	Balance Problems			M I E T	Breast Lump		
N	Pigmentation	1	<u> </u>		Dizzness	<u> </u>		MA	Sore on Penis		
	Other Skin Problems*	<u>}</u>	. 3	AU S	Fainting Spells	<u> </u>		^	Erection Difficulties		
	Irregular Heartbeat			٦	Speech Problems	<u> </u>			Other*		
	Shortness of Breath	<u> </u>			Other*	<u> </u>	<u> </u>		Breast Lump		
c	Low Exercise Tolerance			8	Joint Pains		_		Nipple Discharge		\downarrow
HE	Heart Flutters	<u> </u>		NE	Joint Swelling		<u> </u>		Vaginal Discharge		
5	Chest Pains		<u> </u>	Š	Muscle Strength Loss			,	Non-Period Bleeding/Spotting		┵
HE	Frequent Coughs			ļ	Muscle Lump or Swelling		<u> </u>	WE	Hot Flashes		
À	Cough up of Blood			Ņ	Lump on Bone	ļ.,	<u> </u>	Q T	Pain with Intercourse	_ _	
7	Wheezing			5	Pains in Back		<u> </u>	E A	Possibly Pregnant		-
'n	Night Sweats			_	Other*		ļ	À	Change in Periods		
N G	Swallen Ankles	<u> </u>		E	Constant Thirst				Pain Other Than With Periods		┷
	Cramps in Legs			000	Most Always Cold	<u> </u>	<u> </u>		Other*		—
	Other*			Ä	Too Warm Most Times	-					-
	<u> </u>			N E	Very Sluggish or Tired	-	<u> </u>				+-
\bigsqcup			!	<u> </u>	Jumpy/Nervous	<u></u>		L			

Explain Other*

Doctor's Use Only - Summary

MEN and WOMEN:		✓ Yes No	Have you recently had p	ein in the stomach which:
Do you frequently have severe headaches?	·			el?
(If yes, answer the following):			is brought on by eating fried	foods, gassy foods?
Do they cause visual trouble?			Awakens you at night?	
Do they occur on one side of the head?			Is relieved by antacid medica	abons?
1 To they awaken you at night from sleep? .				g? □ [
) they feel like a tight hat band?				idiately after?
On they hurt most in the back of the head i				ment?
Does aspinn relieve them?				
✓ Yes No		✓ Yes No	Do you frequently have:	
1 7		r had a convulsion?		A sore tongue?
(•	? 🗆 🗖	Trouble swallowing?	
Spells of weakness of arm or leg?.	Pains in ear?		Hoarseness?	🗅 🗅
Ringing in ears?	Nosebleeds?			
Have you ever had shortness of		Have you had pain or ti	phtness	
breath?	✓ Yes No	in the chest which begit	Ta: ✓ Yes No	✓ Yes No
Doing your usual work?	🗆 🗖 🖠	When exerting yourself?		Radiates down the arm?
Climbing a flight of stairs?		When walking against a win	a?	Disappears if you rest?
Which swakens you at night?				Occurs only at rest?
Do you have a chronic cough?		_		When walking fast?
Which causes you to cough?				When walking in cold weather?
}				If you have chest pain or beginness please explain
Accompanied by wheezing?		•	_ :	•
Have you ever coughed blood?		Do you sleep on more than	one pillow?	
Do you cough up much sputum?				
Have you had? ✓ Yes No	When or sir	ice when?	Have you recently had:	✓ Yes No When or since when?
Burning when urinating?			Pains in calves of legs when	1
Loss of control of bladder?			walking?	
Blood in the urine?			Cramps in legs at night?	
Dark colored urine?			Pain in the big toe?	
Trouble starting to unnate?			Varicose veins?	0 0
_			B	
Trouble holding the unge?			t Phileomis of Inflamed led vein	187
			Philebrits or inflamed leg veir Swelling in the ankles?	
To get up frequently at night?			Swelling in the ankles?	
To get up frequently at night?			1	0
To get up frequently at night?	abit		1	Describe briefly your present medical
To get up frequently at hight?	abit ✓ Yes No		1	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes №	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes №	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should
To get up frequently at night?	abit ✓ Yes No	When or since when?	Swelling in the ankles?	Describe briefly your present medical symptoms and anything else we should

,

į

FAMILY AND PERSONAL HEALTH HISTORY Note: Please complete all information on this record. All information is treated in confidence and will not be released unless you grant permission. ____ Birthdate ___ __ Today's Date __ Age ___ Name. _ Daytime Phone Last Physical Examination Date _ Decupation . DADGET **FAMILY RECORD** BROT ING **OPERATIONS** No Date Yes SISTED Check () condition(s) and relation-MOFILE ship of any blood relative who has Tonsils 50 or has had any of the conditions **Aibnecd** A listed below Gall Bladder Alcoholism Stomach Allergies Kidney Anemia Calon Arthritis Thyroid Asthma Hernia Birth Defects Breast (women) Bleeding Tendency Uterus (women) Cancer, tumor Ovaries (women) Colitis Prostate (men) Congenital Heart Other - If yes, what: Diabetes Do you: If yes, daily consumption Emphysema Smoke Pkgs. Epilepsy Drink Coffee Cups Glaucoma Beer ozs. Goiter Hard Liquor ozs. Hay Fever Heart Attack **IMMUNIZATIONS** eart Disease Pneumonia Vaccine High Blood Pressure Tetanus Kidney Disease Booster 🛷 Leukemia Measles Liver Disease nimenza Mental Illness 1 Garman Massles/Mumps Migraine Other - If yes, what: Nervous Breakdown X-RAYS Obesity When was last mammogram? Rheumatism Back Rheumatic Fever Chest Sickle-Cell Anemia Colon Stomach Ulcer Extremities Stroke Gall Bladder Suicide Kidney Tuberculosis Stomach **FAMILY MEMBERS** Treatments Deceased Living Other - If yes, what: Health Cause of Death Doctor's Use Only — Summary Father Mother Prother(s) Sister(s)

PAST AND PRESENT MEDICAL PROBLEMS

Check (✓) all items either yes or no and give approximate date if past.	No	Yes	Yes Past	If Past Date	Check (<) all items either yes or no and give approximate date if past.	No	Yes Now	Yes Past	If Pas Date
Asthma					Skin Disease				
Abnormal Electrocardiogram					Serious Depression				
Angina					Serious Emotional Problems				
Anemia (Type)				i.	Tuberculosis			ļ .	
Arthritis		Ţ	i		Thyroid (overactive)				
Blindness Either Eye					Thyroid (underactive)				
Broken Bones					Varicose Veins				1
Cataracts					Men				
Chronic Bronchitis / Chronic Lung Disease					Prostate Problems				
Cirrhosis of Liver				1	Women				
Colon or Bowet Trouble	_				Menstrual Difficulties				1
Deafness					Cystitis				
Dysentery					Mastitis				
Diabetes	1				Ovarian Cyst				_
Ear Infections					Breast Cancer			<u> </u>	
Emphysema					Other Breast Disease*			-	
Enlarged Heart					Other Gynecological Problems*				
Glaucoma					Still Menstruating				
Gall Stones	1				Age Periods Started				
Gout					Age Periods Stopped				
Goiter					Why Periods Stopped				
Ponorrhea					Number of Pregnancies				
Hay Fever			}		Number of Children				
Heart Murmur as Adult					Number of Miscarriages				
Heart Attack					*Explain:				
High Blood Pressure									
Hepatitis									
Hemorrhoids									
Kidney Infection					Hospitalizations/Reason	0	ate .		
Kidney Stones									
Nervous Breakdown									
Poor Blood Clotting									
Polio					Do you wear artificial devices?	yes	n.)	
Phiebitis					Please list				
Rheumatic Fever									
Rectal Trouble									
Recurrent Boils					Do you have allergies?	yes	n	,	
Stroke					Please list				
Stomach or Duodenal Ulcer									
Syphilis	1								

Doctor's Use Only — Summary

PART A		_			14116	
CAISER-PERMANENTE HIS FORM IS TO HELP YOUR	MEDICAL CENTE	IT ETTER HEALTH CARE THE	E INFORMATION IS			
ONFIDENTIAL IT WILL BE PAR	T OF YOUR MEDICAL R	ECORD.				
				1		
HOME ADDRESS						
CITY	HOME TELEPHON	IE NUMBER BUSINESS TELEP	HONE NUMBER			
,	4.	5.			IMPRINT ARE	A
OCCUPATION	AGE	1		GHT	DATE OF BIRTH	1
	7.	8.	9.		10.	ا
AST MEDICAL HIS	STORY					
HAVE YOU RECENT	TLY ENROLLED	IN KAISER? 🗆 YE	ES 🗆 NO			••
DO YOU HAVE A F	-			ARA?	YES INO	
WHEN WAS YOUR	LAST COMPLET	TE PHYSICAL OR	MULTIPHASI	C EXAM	? 🗆 1-2 years ag	go 🗆 3-4 y
HOSPITALIZATION	C AND OPERAT	IONS.			□ 5 years or n	nore
	•				•	
_	Reason for H				-	
В						
E						
Asthma Blackouts Bladder Infection Cancer Chickenpox Diabetes Emphysema Fractures Gallstones		Kidney Infection Kidney Stone Heart Attack High Blood Pressu Malaria Measles German Measles Mononucleosis Mumps Pneumonia	ure (Spleed Stroke Stroke Stroke Thyroid Tuberd Ulcers Undes Venerd	- C:	
☐ Glaucoma	U	Treathorna	-			
☐ Gout		Theumonia	•			
Gout	35 years of age ast Tuberculin T	e, have you ever t est? □less than 5	had a positiv years aao [e skin te Imore th	st for Tuberculosi	s? 🗆 YES 🖂
IMMUNIZATIONS: A.If you are under B. When was your in	35 years of age ast Tuberculin T ast Tetaņus shot	e, have you ever hest? Diess than 5 P:Diess than 10 ye	had a positív years ago [ears ago[m	e skin te Imore th ore than	st for Tuberculosi	s? 🗆 YES 🖂
IMMUNIZATIONS: A.If you are under B. When was your in	35 years of age ast Tuberculin T ast Tetanus shot ALLERGIES TO	e, have you ever hest? Diess than 5 P:Diess than 10 ye	had a positiv years ago [ears ago]m please write	e skin te Imore th ore than	st for Tuberculosi	s? 🗆 YES 🖂
IMMUNIZATIONS: A.If you are under B. When was your IC. When was your ILIST ALL KNOWN Name of DIA.	35 years of age ast Tuberculin T ast Tetanus shot ALLERGIES TO I	e, have you ever hest? Diess than 5 ?Diess than 10 you DRUGS: (If none, Describe re	had a positiv years ago [ears ago [m please write eaction	e skin te Imore th ore than none.)	st for Tuberculosi an 5 years ago a 10 years ago⊡	s? □YES □ □do not kr do not kno
IMMUNIZATIONS: A.If you are under B. When was your in C.When was your in LIST ALL KNOWN Name of Di A. B.	35 years of age ast Tuberculin T ast Tetanus shot ALLERGIES TO rug	e, have you ever t est? Diess than 5 ?Diess than 10 yo DRUGS: (If none, Describe re	had a positiv years ago [ears ago]m please write eaction	e skin te Imore th ore than none.)	st for Tuberculosi an 5 years ago 1 10 years ago ()	s? □YES □ □do not kr do not kno
IMMUNIZATIONS: A.If you are under B. When was your In C. When was your In LIST ALL KNOWN Name of Di A. B. C.	35 years of age ast Tuberculin T ast Tetanus shot ALLERGIES TO rug	e, have you ever t est? □less than 5 ?□less than 10 yo DRUGS: (If none, Describe re	had a positive years ago [mage] more pears ago [mage] more please write eaction	e skin te Imore th ore than none.)	st for Tuberculosi an 5 years ago a 10 years ago□a	s? □YES □ □do not kno do not kno
IMMUNIZATIONS: A.If you are under B. When was your In C. When was your In LIST ALL KNOWN Name of Di A. B. C.	35 years of age ast Tuberculin T ast Tetanus shot ALLERGIES TO rug	e, have you ever t est? Diess than 5 ?Diess than 10 yo DRUGS: (If none, Describe re	had a positive years ago [mage] more pears ago [mage] more please write eaction	e skin te Imore th ore than none.)	st for Tuberculosi an 5 years ago a 10 years ago□a	s? □YES □ □do not kno do not kno
IMMUNIZATIONS: A.If you are under B. When was your I.C. When was your I.C. When was your I.C. A	35 years of age ast Tuberculin T ast Tetanus shot ALLERGIES TO rug	e, have you ever t est? □less than 5 ?□less than 10 yo DRUGS: (If none, Describe ro	had a positive years ago [mage] makes ago [mage] please write eaction	e skin te Imore th ore than none.)	st for Tuberculosi an 5 years ago 1 10 years ago	s? □YES □ □do not kr do not kno
IMMUNIZATIONS: A.If you are under B. When was your in C.When was your in LIST ALL KNOWN Name of Di A. B. C. D. MEDICINES: Include	35 years of age ast Tuberculin T ast Tetanus shot ALLERGIES TO rug	e, have you ever the est? Diess than 5 than 10 you be compared to the estimate of the estimate	had a positive years ago [mage] please write eaction	e skin te Imore th ore than none.)	st for Tuberculosi an 5 years ago 1 10 years ago	s? □YES □ □do not kra do not kna
IMMUNIZATIONS: A.If you are under B. When was your in C.When was your in LIST ALL KNOWN Name of Di A. B. C. D. MEDICINES: Include	35 years of age ast Tuberculin T ast Tetanus shot ALLERGIES TO I rug de Birth Control pription drugs if k	e, have you ever the est? Diess than 5 ? Diess than 10 you ever the est? DRUGS: (If none, Describe response) Describe response, and chown.	had a positive years ago [mage] please write eaction	e skin te Imore th ore than none.)	st for Tuberculosi an 5 years ago 1 10 years ago	s? □YES □ □do not kr do not kno

AMILY MEDICAL HISTORY ANY BLOOD RELATIVES HAVE AD ANY OF THESE			7	\$/	7		Age if Age at Cause of Living Death Death
ONDITIONS, PLEASE CHECK /HO?	Fother	Mother	on or	Bromer Side	500	21.	Father
Alcoholism Arthritis Asthma, hayfever Cancer Which part of body?	0000	*0000			30000	21.	SISTERS AND BROTHERS How many have you had? If any are deceased, give age and cause of death: Age Cause of Death
Cancer of Colon Diabetes Emphysema Epilepsy Gallstones Glaucoma Heart Attack Heart Attack Heart Attack before age 45 Other heart conditions Kianey Disease (nephritis) Leukemia Liver. Sickle cell anemia Stomach ulcers Stroke before age 45 Suiciae or mental illness Thyroid disease Tuberculosis ERSONAL HISTORY 23. MARITAL STATUS: (Check of Married © Divorced © Re 24. OCCUPATIONS: Present Occup	-mar				000000 00 00000000 ×		□Write in any other conditions not already listed the run in your family □ Do not know my family history. CHILDREN (List age. Describe any problems.) A. □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □
A. You:				····	-		
B. Spouse:					-		
28. ALCOHOLIC DRINKS: 🗆 nev	S? [EST /er ES W	YES X-RA fre	.Y? [quer SHE '	less t WAS cle)	tha dai	n 3 ye ily 🗆 GNAN	ars 🗆 less than 5 years 🗀 do not know
. FOR WOMEN ONLY: A. Has your mother or sister hi B. Do you come regularly to hi C. Was your last PAP Smear Te	(aise	r for	a PAF	² Sme	ear T	est? [□ YES □ NO

р 1

8. Major findings from Physical Examination

9. Somatic diagnoses

 Recommendations/ Plan

11. Signature, title

☐ Continued

MEDICAL HISTORY AND REVIEW OF SYSTEMS

Admission Annual Other

Confidential Client/Patient Information See W & I Code Section 5328

MH 5705 (11/82) CRDM Reference 2420

State of California				
Date of Examination:		Instructions:		t be completed in narrative mal or abnormal findings
Date Typed:			meiggeg.	
CATEGORY	COMMENTS			
CATEGORY A. GENERAL Appetite or weight change Chills, fever, night sweats Vergito, Syncope Sleep disturbance Prone to infection Rapid loss of hair Fatigue Other B. EENT Visual: change, diplopia, phopphobia, fields Hearing: Loss, tinnitus, discharge Nose: Epistaxis, discharge, polyps Teeth, dentures Bleeding gums, cheilosis Frequent sore throats, hoarseness, redness Smell, taste Other C. RESPIRATORY Shorness of breath, wheezing Frequent colds, cough Dyspnea on exerttion Hemoptysis Cyanosis Other \text{NDIOVASCULAR} \text{nest pains, other discomfort} Orthopnea Hyper-,Hypotension Palpitations, tachycardia Murmurs, Claudication Edema Varicosities Other E. GASTROINTESTINAL Jaundice Dysphagia, heartburn Nausea, vomiting abdonimal pain Food intolerance Hematemesis, melena Food intolerance Hematemesis, melena Food intolerance Hematemesis, melena Bowel habits, change Hemorrhoids, rectal bleeding Other (Continued on reverse side)				

Confidential Client/Patient Information
See Welfers & Institutions Code Section 5328

State of California Health and Welfare Ag	Pency	<i>(</i> ►		Department of Mental H
((₹	•	•
CATEGORY	COMMENTS			
T. GENITOURINARY &				
GYNECOLOGICAL				
Frequency, nocturia, dysuria,				
pyuria, hematuria, retention incontinence, dribbling			,	
Impotence, ejeculation problem				
Prostate	[•		
Fertility, Birth Control				
Abnormal menses, menopause Dyspareunia				
Genitalia				
Venereal Disease				
Sexual dysfunction				
Masses, drainage, discharge Hernia, hydrocele				
Pelvic pain				
Other				
G. MUSCULOSKELETAL Joint pain, stiffness, swelling				
Muscle Weakness				
Deformities				
Tenderness				
Other H. NEUROLOGICAL				
Personality changes				
Stroke				
Parathesia Paralysis				
Balance, coordination				
Headache			,	
Seizures, loss consciousness				
Tremor, rigidity, restlessness Other involuntary movements				
her				
I. INTEGUMENTARY				
Pruritis, rash				
Dryness, eruptions Nodules, lumps				
Other				
J. ENDOCRINOLOGICAL				
Polydipsia Heat or cold intolerance				
High, low blood sugar				
Polyuria				_
Other K, HEMATOLOGICAL				
Anemia				
Lumps				
Bleeding, Clotting Prone to infection				
Other				
į				
1				
ļ				
M.D. Signature				Date
MEDICAL HISTORY & R	EVIEW OF SYSTE	MS		
☐ Admission ☐ Ar	nnual 🗆 Other			
Confidential Client/Pat				
See Welfare & Institutions	Code Section 5328		•	

			REFLE	XES			<u>R</u>	<u>L</u>				
NOPMAL	2-		Bicep	s								
INCREASED			Trice	•					•			
DECREASED	i -		Patel Actil						•			
ABSENT	. 6		Plant		•		·	 -	•			
(Underline reinford			Plant	ai					-			
reintord	EG 1		Ankle	clon	us?		Present	/Absent				
ROMBERG			GAIT	AND S	TATION							
			OTHER	FIND	INGS							
·			ABNGR	MAL I	NVOLUN	TARY	MOVEMENT	SCALE				
LYSTRUCT			,				,	FR	EQUENCY	n	NTENSI	TY
	mouth is								merator)	(dei	nomine	tor)
	e as to cu							0 - 1	bsent	/ N	one	• 0
	etient is							1 - R	3.50	, w.	inimal	- 1
							OBLABESHS			Ι,		- 1
	e movement (LE)			necol	d INCE	a 10	wer	2 - 0	ccasiona	L / H:	ild	= 2
	mity (LE) stient is				fa= -	ha===	erheroid	3 = 5	requent	/ ×	oderat	e = 3
	extremit				TOL C	MOLEO.	erneraid	i	•	٠,		_
	cxtremit congue :				f 0===	mostel	h ("Ta")	1 4 - C	<u>'antinuou</u>		a-ked_	- 4
Observe	tongue p	esting	אין אי	501 G.	Lopen	BOGE	. (111).		Examp	<u>le:</u> ency Rar:	./:	
				<u> </u>					- Irequi	incy Kat	-/ 1000	datty
	l		CHOR	EOATH	ETOID	DADY	INSONISM		0.11	<u>ier</u>	i	
	TONG	ÜΕ		VENEN			mor:	Ak	athisia;			
						1 .	mor: (regular,	1 -	adykinesi	.a;	1	SIG
DATE	Spot:	taneous	- (seless	l i	rhychmic)		stonic po		İ	AND
	1 + 1	Ī	1	irreg	ular	*			ooling	,	1	
	l la	Out	Face	UE	LE	1	Rigidity	Ir	uncal Mov	epents.	1	
			1 /	1 /	1 /		1				<u></u>	
	//		/									
	1/1/	/ /	1	1/								
		/ /	1	1	1/		 					
	//	<u> /</u>	1./		1/							
NCLUSIONS/D	IAGNOSTIC	Impress	IONS									
COMMENDATIO	NS/PLANS						 		······································			
zamining Physicis	10 S. 23 St. 23						Title					
	n any arute						* 1116			Unit		
	<u> </u>		··		PAG	GE 3	dr 3	· · · · · · · · · · · · · · · · · · ·				
	PHYSICA	L EXA	TANIN	ION								
	Admiss	non		Annual								
	☐ Other			=								
							Į.					
	Confidentia'	C1 /D	ene lata-	mation					•			

	GUIDELINES	Date of Report: Date of Dictation:	
	History of present physical illness and presenting problems	Date Typed:	
2.	Past medical and medication history		
3.	Allergies		
4.	Family health history		
5.	Review of systems (record both positive and negative)		
	a. Integumentary system		
	b. head, ears, eyes, nose, throat		
	c. respiratory		
	d. cardiovascular	and the second of the second o	
	e. gastrointestinal		
	f. genitourinary		
	g. musculoskeletal		
	h. neurological		
	i. endocrinological		
	j. gynecological		
	k. hematological- lymphatic	-	
6.	Recommendations and provisional diagnosis		
7.	Signature		
			Continued

Evaluation Report
MEDICAL HISTORY AND REVIEW OF SYSTEMS

INSTRUCTIONS: 1) Wherever possible indicate relative "degree" or amount.

2) For unusual findings use additional pages as necessary.

(CONTINUE ON REVERSE SIDE)

ight	Weight		Age
lanaal Ohaamanian			
eneral Observation	Build, development, nutrition, evidence of injury		
	Activity, cooperation, responsiveness		
kin			
•	Cyanosis, bruises, scars, Jaundice, moisture, color, eruptions, hi		
ead	Shape, symmetry, tenderness, bruit, circumference	Facies	Symmetry, expression
Scalp	Bruises, siopecia, condition of heir, scars		·
E		Nana	
Ears '	Anomalies, discharge, tophi, drums, aculty	No=	Obstruction, perforation, discharge
Eyes•	Lids, arcus, conjunctives, exponthalmos, edema, acuity		
Mouth			
Moduli	Breath, teeth, gums, phormes, tonque, mucosa, sores, yauit		
Throat	Palate, tonsiis, pharynx, exudate		
eck	Page (totalia, prierytra, azocata		
	Pulsation, thyroid, lymon glands, scars		
hest	Shape, symmetry, deformity, dyspnes, rosary, lag, retraction, p		
Breasts			
010430	Scars, masses, tenderness		
Lungs	Fremitus, duliness, flatness, breath sounds, raies, rubs, cough		
Heart			
; real(Thrill, cardiac snock, apex beat, arrhythmia, boundaries, shift,	murmurs, transmissi	ons
	Distribution, radiation, bruit, accentuation, reduplication		
ascular System			
Pulse Equality, r	nythm, syncrony, rate, walls, capillary pulsation	i Pressure	Systolic, diastolic
bdomen			
	Shape, symmetry, distension, scars, striae, tympany masses, spa	ism	
	Tenderness, fluid, hernia, varies, organs feit, boundaries		
enitalia			
	Scars, discharge epididymis, hydrocele, varicocele, tenderness		
pine	Kyphosis, lordosis, scallosis, rigidity, tenderness		

PHYSICAL EXAMINATION

Confidential Clant Information See W& / Code, Sections 4514 and 5328

Rectum					
Extremities					
Joints, Bones					
Lymphatic System					
NERVOUS SYSTEM (F	or detaile	d neurological examination	, use form OS 5513):		
Muscles: -Strengt	h			_ Tone	
Coordination	·•			Atrophy	,,
Babinski		Ga	it	Romberg	
Abnormal Movem	ent				
Deep Tendon Ref	lexes				
Superficial Reflex	es				
Sensations					
Cranial Nerves					
HEARING AND VISUAL SCREENING:		Can hear without difficulty	Hearing impaired	☐ Needs hearing acuity/audiometric evaluat ☐ Needs visual acuity/ophthalmology exam:	
GENERAL SUMMARY	:				
IMPRESSION (Psychiat	tric and S	omatic):			
				·	
Data		Warri	(Signed)		M D

PHYSICAL EXAMINATION

Confidential
Client Information
See W& I Cor. | tions 4514 and 5328

18408 OXNARD STREET TARZANA. CA 91356 (818) 996-7300 • CALIF (800) 382-3322

DIRECTOR AND PATHOLOGIST PAUL T. WERTLAKE, M.D.

SITE:

ANNUAL PHYSICAL

MYRON SAMPLE 234 MAIN STR ANYTOWN, CA	EET													L R סהוסם _ (JLTS IN	I A.M.
			AC	COUNT	. NC).	123	345					STA	TIAD	OTIO	NAL FEE F	OR PICK-L
PLEASE PRINT CLEARLY		ALL	INFORM	ATION N	JUST	BE	PRC'	VIDED OR A	CCOU	NT W	ILL S	BE BILLE	D.				
ATE COLLECTED REFER	TRING PHY	SICIAN											SOCIAL	. SECL	RITY :	CA 01	
ATIENT'S LAST NAME		~	Fil	RST								мі			\top	00B.	
M DF			ORAV T	ME	ROOM	VO .			URINE V	OL 241	HAS	ML.			FAST	/ r-G	HAS PP
	-25 1 1 P V	8 1 1 1 1	i Haring	(J. 30.52)	- 1 TH		175		W.		2 i g	101 <u>0.</u> (= 30)(1	454		: 1: L	21. (1)	\$2.20
JILL TO: E CUR ACCO	UNT		PATIENT		NSUR	ANCE	=	☐ MEDICA				CAL/CA					
ESPONSIBLE PARTY								NSURANCE	COMPAN	VY.							
ODRESS								ADDRESS									
ITY / STATE / ZIP CODE		,						LI CITY STAT	E / ZIP CO	DDE.							
								11									
HONE NO								CERTIFICAT	re no.				G	RCUP '	40		
COS CODE (DX) (SEE BACK)					·			A EDICAD	MEDICAR	E NO.					-	STATE	
	Mederica	Phone 1	ನಿಂ≐ಟೆಗಾ	6 1 N 2 1 1	11110	51 <i>2</i> 5	C 11	1.1	1 1 2:01=4	1 7 7 1 1 1	1 1	- ! ! ! - (*)&%		Ayes.	200		A Contract
2211 CHEMPANEL(CP)(INCLUDES HOL)		_	S					LUCRESCENT)			S.L					B SURFACE	
23 12 CP. T.			2					HOL/LOL. APO A1/	B. LIPIO SI	CORE)	S					FILE (SEE BA	
2402 CP. CBC			S.L	2806 €	D RISK (5050.	LIPIO F	PHE(40)			s	5335 CC	MPREHE	NSIVE L	LUPUS F	PROFILE (SEE	BACK)
3000 CP CBC. T-			S.L	5009 EL	ECTROLY	TE PR	OFILE	(Na. K, CHOLORIDE	. CO ₇)		s	1855 Ali	DS 1.D. (H	IV ELIS	A WES	TERN BLOT R	EFLEXI
2403 CP. CBC. UA			S.L.U	5005 TH	IYROID P	ROFILE	E = 1 (1	TyU, T. RIA, T.)			S	1387 9A	SIC AIDS	(HELP	ER & S	UPPRESSOR	CELLI
TE CP. CBC, UA, T3U, T4 RIA, T-			S.L.U	2642 HY	POTHYR	OIO PR	OFILE	(T;U, T, RIA, T, HS	(HST-		S	2904 M6	NOPAUS	AL PRO	FILE (F.	SH, LH)	
CP. CBC, UA, RPR. T U, T, RIA, Tr			S.L.U	3535 HY	PERTHY	ROID P	ROFILE	(FREE T., T.U. T.	RIA. T,)		S	3659 CH	ILAMYDIA	4 & GO!	CARHE	A PROFILE (MA PROBES)
UP, CBC, UA, T ₂ U, T ₄ RIA, T ₇ LIPIO	SCORE		S.L.U	3416 INI	TIAL DIA	GNOST	TIC HEP	ATITIS PROFILE (SI	EE BACK)		S	3347 PR	ENATAL	#1 (W/I	RAEG	ANTIBODY SO	REEN)
3279 ANEMIA PROFILE (FOLIC ACID, VIT	r. B., CBC)		S.L	6272 CC	MPREHE	NSIVE	HEPAT	ITIS 8 PROFILE (SE	EE BACK)		5	5704 PR	ENATAL	# 2 (33)	47 W/H	iep. 8 surfa	CE ANTIGENI
3341 ANEMIA PROFILE (3279, FERRITIN			S.L					NOME PROFILE (SE	E BACK)		S	5756 UF					
5015 ARITHRITIC IRA. CRP ESR ASO U			S.L					CHEMISTRIES)		a stature a	S					_ MARUUAN	
0395 ACID PHOSPHATASE, TOTAL			CYTOMEGAL					UTHIUM	1=-11:15	R	0380			Š		CHLAMYDIA.	ONA PROBE
0833 ACID PHOSPHATASE, RIA P.A.P.	FS S		DIGOXIN	JAINOS ICHIA	, ida 3			LYME DISEASE AI	R	s		SEDIMENT.	RATE	L			DNA PROBE
0108 AMYLASE	s		DILANTIN		. s		8224		•	s		T, UPTAKE		s		GRAM STAIN	
0611 ANA FLUORESCENT	s		ELECTROPHO	RESIS. PROTI	EIN S	;		MONO SPOT		s		T. RIA (THY				OVA & PARA	
0822 BETA HCG, QUANT.	s	0832	FERRITIN		S	;	0291	OCCULT BLDOO		•	1357	FREE T.		s	1354	UREA/MYCO	PLASMA CULTUF
0556 BETA HCG, QUAL.	s	0650	FSH		S	;	0777	PHENOBARBITAL		R	8455	TESTOS.TL	SERUM	S	0391	WET MOUNT	
0361 BLOOD TYPE/RH	LA	05 12	FOLIC ACIO		S	•	0309	PT		В	0671	TSH (HS)		S	0100	CULTURE, GE	NITAL GC ONLY
0132 BUN	S	0535	GLUCOSE FA	STING	G	iy .	0296	PTT		8	0823	THEOPHYLL	INE	S	010 0	CALTURE/SE	NS GENITAL RO
0129 CBC W/PLATELET COUNT	L	0967	HERPES I, IG	G, SERUM	S	;	5013	PREMARITAL FEN	MALE	S	0372	URIC ACID		S	1378	CULTURE, HE	RPES
1780 CEA (ROCHE)	Ĺ		HERPES II, IG		S			PREMARITAL, MAI	LE	S		UA W/MICR	0	U		CULTURE/SE	
0387 CEA (HYBRITECH)	S		HOL CHOLES					POTASSIUM		S		VIT B _e		S		CULTURE, ST	
6311 CHEMPANEL W/O HOL	S		HEP B SURFA		_			PROGESTERONE		S	(OTHER T	:515				ROAT, BETA-STR
0151 CHOLESTEROL	S	•	HIV (HTLV III)		S			PROLACTIN	004	S							NS., THROAT, RC
0785 CORTISOL, PLASMA	S	1387	HELPER-SUP	PHESSOR T-C	æιL)	Τ.	2422	PROSTATIC AG &	rsa -	FS					0100	LULIURE/SE	NS. URINE. ROUT

0444 CFK, ISOENZYMES FS 0545 IMMUNOGLOBULINS 0316 RA FACTOR S 0100 CULTURE/SENS. WOUND

0320 RUBELLA

s

REFEESIMATE (IDENAUGED STORY) EASE SURF CEDESTRED PROFITE (STORES MITTHER (STORES AND MITTER (STORES AND MITTHER AND

development from the constitution 1234 CHEM, CBC, UA 0257 IRON/IBC

6311 CHEMPANEL

29 CBC

0160 CREATININE, SERUM

3 UA

OTHER PROFIL	ES		\Box ,			\Box ,				\Box ,									
S-Soun Barrier Tuce FS-Frozen Serum	R-Red Top (8 6 see Tex	Gn-Gree Gy Grey		- Lavendor - Random	C80. inc.	Blood Sine	ari Y-Y	rellow Too ine Refere	ACDI Ince Manus	at Y	SST	S P	SL	G,	8	Я	u s	ı c	T

PROFILE COMPONENTS

3416 INITIAL DIAGNOSTIC HEPATITIS PROFILE 2691 COMPREHENSIVE EPSTEIN BARR PROFILE HEPATITIS A ANTIBODY, TOTAL EPSTEIN BARR VIRUS (VCA), IgG ANTIBODY HEPATITIS A ANTIBODY, IGM EPSTEIN BARR VIRUS (VCA), IgM ANTIBODY HEPATITIS B SURFACE ANTIGEN EPSTEIN BARR VIRUS EARLY ANTIGEN, ANTIBODY EPSTEIN BARR VIRUS NUCLEAR ANTIGEN, ANTIBODY **HEPATITIS B CORE ANTIBODY** HEPATITIS B SURFACE ANTIBODY 5335 COMPREHENSIVE LUPUS PROFILE 6272 COMPREHENSIVE HEPATITIS B PROFILE ANA FLUORESCENT HEPATITIS B SURFACE ANTIGEN ANTI-DNA (IF ANA POSITIVE WITH TITER 1:80 OR HIGHER) HEPATITIS Be SURFACE ANTIGEN ANTI-ENA (ANTI-Sm & ANTI RNP) HEPATITIS Be ANTIBODY ANTI-MITOCHONDRIAL ANTIBODY HEPATITIS B CORE ANTIBODY COMPLEMENT C4 PARIETAL CELL ANTIBODY, IFA HEPATITIS B CORE ANTIBODY, IdM HEPATITIS B SURFACE ANTIBODY SMOOTH MUSCLE ANTIBODY SSA/SSB 6273 HEPAJITIS VIRAL SYNDROME PROFILE THYROID MICROSOMAL ANTIBODIES HEPATITIS A ANTIBODY, TOTAL HEPATITIS A ANTIBODY, IgM HEPATITIS B SURFACE ANTIGEN HEPATITIS B CORE ANTIBODY HEPATITIS B SURFACE ANTIBODY EPSTEIN BARR VIRAL CAPSID ANTIGEN EPSTEIN BARR VIRAL CAPSID ANTIBODY, IgM CYTOMEGALOVIRUS (CMV) ANTIBODY, IgM

DIAGNOSIS CODES

Abdominal Pain	789.0	Headaches/Migraine 346
Abscess	682.9	Hematuria
Anemia		Hepatitis
Angina	413	Hypercholesterolemia
Arteriosclerotic Heart Disease		Hyperthyroidism
Arthritis, Rheumatoid		Hypoglycemia
Asthma		Hypokalemia 276.8
Back Pain		Hypothyroiaism 244.9
Bronchitis	466.0	Labyrinthitis
Chest Pain	786.5	Mononucleosis
Chronic Pulmonary Disease	416	Myocardial Infarction
Congestive Heart Failure	_	Normal Pregnancyv22
C.V.A		Osteoarthritis
Diabetes Mellitus		Possible Pregnancy
Diarrhea	558.9	Seizure Disorder
Esophagitis		Thrombophleaitis
Essential Hypertension		Tonsillitis Acute
Fatigue		Transient Cereb Ischnemic Attack
Flu Syndrome		Ulcer
Gastritis		Upper Respiratory Infection
Gastroenteritis		Urinary Tract Infection
Gout		Vaginitis
		•

MICROBIOLOGY SPECIMEN REQUIREMENTS

0100	_	Swah	~-	C+.	arila	Contr	ninar
4 5 1 4 11 4	•	>wan	Λſ	~ 11	Priis	1.0012	amer

0234 - Air Dried Smears in Slide Jacket. Specify Source

0292 - Random Stool in PVA or in Clean Container, Tightly Sealed

0388 - Gen Probe Media

0391 - Swab or Material in Culture Transport

0420 - Gen Probe Media

0485 - Swab in Transport Media

1354 - Mycoplasma Transport, Frozen

1378 - Scrape Lesion with Swap, put in Viral Media

Clinical Laboratorie				TESTS REQUES	TEO BY	
Con severe aide for all l		_			·)
See reverse side for all to		FIRST			4. m *	
TAILEAT I						ĺ
		<u> </u>		e	•••	
PATIENT I.D. NO. ROOM	NO. ADDITION	NAL I.D. NO.				1
						1
AGE SEX FASTING DATE C	COLLECTED TIME C	CLLECTED		**		1
YES NO		\		Sold to the State of		1
PHYSICIAN NAME	PIN #)
				FOR LAB USE	ONLY	$\overline{}$
BILL ACCOUNT PATIENT TO	MEDICARE / MEDICAL	HMQ / IPA	Į.			
PATERT BALLED W						
and when purchase in the section of	named to the property of a good party.	THE CHARLES PARTY IN THE COMPANY OF				
GATIENT - DESCONCIOLE GARTY		l BH	ONE NO.		HAND BUT THE THEODIAN	<u> </u>
PATIENT / RESPONSIBLE PARTY)		HMO BILLING INFORMATI)
ADDRESS			'	 ·	ONE 4 BACK OF LO. OR COMPLETE	THE FOLLOWING
AUUNE33				BELING ADDRESS		
CITY, STATE		ZIP CODE	DATE OF BIRT		STREET OR P.C	9 80 z
GIT, SIMIE	Í	1 1 1 1	1 I	Ì	CITY STATE	
MEDICARE NUMBER	SUFFIX MEDI-CAL	NUMBER	4	PATIENT 10 #	GROUP #	N.E)
	HEDROAL.			1 SELF	Short United	one•
STAT CA	LL BACK COMM	ENTS CLINICAL IN	EOBMATION OF	MEDICAL HISTORY	(TOTAL VOLUME	
-		Р	ROFILES			
 06724-3⊑_ Chem-Zyme Plus Evaluation	07559-3∐ Chemzy	p me Evaluation		Hepatitis Panel, A	cute 07101-6	Prenatal Evaluation
04001-8 Master Chem	07702-21 Compler	me Evaluation ment Evaluation	07855-1 C	Hepatitis Profile, C	Diagnostic 04012-8	Prenatal Profile, Ro
04001-8 Master Chem 06005- Arthritis Profile, Routine	07702-2 Complete	me Evaluation nent Evaluation ensive Health Evalu	07855-1 C F 1 01001-0 C ration 04017-2 C	Hepatitis Profile, Cor Hepatitis Profile, Cor	Diagnostic 04012-8 Diagnostic 06008-2 Diagnosti	Prenatal Profile, Ro Prenatal Profile, Com
04001-8 Master Chem 06005- Arthritis Profile, Routine 07402- Arthritis Evaluation II	07702-2 Compler 06202-9 Comprend 06324- Electroly	me Evaluation ment Evaluation ensive Health Evalu ite Panel	07855-1 \$\tilde{\text{F}}\$ \ 01001-0 \text{ation} \ 04017-2 07857-3	Hepatitis Profile, Co Hepatitis Profile, Con Hepatitis B Monito	Diagnostic 04012-8 Imprehensive 06008-2 Imprehensive 01031-8 I	Prenatal Profile, Ro Prenatal Profile, Com Prostate Panel, Dia
D4001-8 Master Chem D6005- Arthritis Profile, Routine D7402- Arthritis Evaluation II D6006-0 Arthritis Profile Comprenensive	07702-2 Complete 06202-9 Comprehe 06324 Electroiv 04003 Executiv	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I	07855-1 F1 01001-0 ation 04017-2 07857-3 06455-9	Hepatitis Profile, Co Hepatitis Profile, Cor Hepatitis B Monito Human Papilloma	Diagnostic 04012-8 1 1 1 1 1 1 1 1 1	Prenatal Profile, Ro Prenatal Profile, Com Prostate Panel, Dia T-Helger/T-Suppress
04001-8 Master Chem 06005- Arthritis Profile, Routine 07402- Arthritis Evaluation II	07702-2 Complete 06202-9 Comprehe 06324 Electroiv 04003 Executiv	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II	07855-1 \$\tilde{\text{F}}\$ \ 01001-0 \text{ation} \ 04017-2 07857-3	Hepatitis Profile, Co Hepatitis Profile, Cor Hepatitis B Monito Human Papilloma	piagnostic 04012-8 mprehensive 06008-2 mng Panet 01031-8 mrus Panet 07849-6 mprehensive 04010-6	Prenaral Profile, Ro Prenaral Profile, Com Prostate Panel, Dia T-Helcer/T-Suppress Thyrold Panel
D4001-8 Master Chem D6005 Arthritis Profile. Routine D7402 Arthritis Evaluation II D6006-0 Arthritis Profile Comprehensive D7406-3 C A R.E. Panel #1	07702-2 Complet 06202-9 Comprend 06324 Electroly 04003 Executiv 04018-3 Executiv	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile II ecutive Profile	07855-1 F 1 01001-0 ation 04017-2 07857-3 06455-9 06007-1 00185-9	Hepatitis Profile, Co Hepatitis Profile, Cor Hepatitis B Monito Human Papilloma Liver Function Panel, Co	piagnostic 04012-8 morenensive 06008-2 ming Panel 01031-8 ming Panel 07849-6 morenensive 04010-6 ma Panel 01002-1 ma Pane	Prenatal Profile, Ro Prenatal Profile, Com Prostate Panel, Dia T-Hetcer/T-Suppress Thyroid Panel Thyroid Panel, Hyp
D4001-8 Master Chem D6005 Arthritis Profile. Routine D7402 Arthritis Evaluation II D6006-0 Arthritis Profile Comprenensive D7406-3 C A R.E. Panel #1 D6905-8 C.A.R.E. Panel #2	07702-2 Complete Comp	me Evaluation ment Evaluation ensive Health Evalu ite Panel re Profile II ecutive Profile H Evaluation	07855-1 F 1 01001-0 ation 04017-2 07857-3 06455-9 06007-1 00185-9	Hepatitis Profile Cor Hepatitis Profile Cor Hepatitis B Monito Human Papilloma Liver Function Panel Co Megaloblastic Anemi	piagnostic 04012-8 morenensive 06008-2 ming Panel 01031-8 ming Panel 07849-6 morenensive 04010-6 ma Panel 01002-1 ma Pane	Prenatal Profile. Ro Prenatal Profile. Com Prostate Panel. Dia T-Hetcer/T-Suppress Thyroid Panel Thyroid Panel. Hyp Thyroid Panel. Hyp
DA001-8 Master Chem D6005 Anthritis Profile, Routine D7402 Anthritis Evaluation II D6006-0 Anthritis Evaluation II D7406-3 C A.R.E. Panel #1 D6905-8 C.A.R.E. Panel #2 D6846-4 C.A.R.E. Panel #3 UNLESS OTHERWISE STATED PLEAS	07702-2 Compler 06202-9 Comprent 06324 Electroly 04003 Executiv 04018-3 Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II cutive Profile H Evaluation INDIV 1 hr op	07855-1 F 01001-0 07857-3 06455-9 06007-1 07100-5 DUAL TESTS	Hepatitis Profile Cor Hepatitis Profile Cor Hepatitis B Monito Human Papilloma Liver Function Panel Co Megaloblastic Anemi	plagnostic 04012-8 morehensive 06008-2 ming Panet 01031-8 ming Panet 07849-6 morehensive 04010-6 ma Panet 01002-1 m i 01003-2 m i 010010-9 m i 01010-9 m	Prenatal Profile. Ro Prenatal Profile. Com Prostate Panel. Dia T-Helger/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyo CIMEN (A) =ROC Vitamin B12 & Fola
DA001-8 Master Chem D6005 Anthritis Profile. Routine D7402 Anthritis Profile Routine D7402 Anthritis Profile Comprehensive D7406-3 C.A. R.E. Panel #1 D6905-8 C.A.R.E. Panel #2 D6846-4 C.A. R.E. Panel #3 UNLESS OTHERWISE STATED PLEAS D2500-3 A80 Group & Rh Type D0287-1 Acid Phosphatase, Prostatic (F)	07702-2 Complete 06202-91 Complete 06324- Electroly 04003- Executiv 04018-31 Executiv 04005-11 Mini-Executiv 03008-51 FSH & L SE REFRIGERATE 01201-21 Glucose 01200-11 012	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II cutive Profile H Evaluation INDIV 1 hr pp 2 hr PP	07855-1	Hepatitis Profile Cor Hepatitis Profile Cor Hepatitis B Monito Human Papillomas Liver Function Panel Co Megaloblastic Anemi Prenatal Evaluatio Premantal, Male Profactin, Serum	Diagnostic 04012-8	Prenatal Profile. Ro Prenatal Profile. Com Prostate Panel. Dia T-Helger/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyo CIMEN (A) =ROC Vitamin B12 & Fola
DA001-8: Master Chem D6005 Anthritis Profile. Routine D7402 Anthritis Profile Routine D7402 Anthritis Profile Comprehensive D7406-3: C.A.R.E. Panel #1 D6905-8: C.A.R.E. Panel #2 D6846-4: C.A.R.E. Panel #3 UNLESS OTHERWISE STATED PLEAS D2500-3: ABO Group & Rh Type D0287-1: Acid Phosphatase, Prostatic (F) D3453 Acid Phosphatase, Total (F)	07702-2 Compler 06202-9 Compreh 06324 Electroly 04003 Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 01200-1 Glucose	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II cutive Profile H Evaluation INDIV 1 hr 'pp erum Qual	07855-1	Hepatitis Profile Co Hepatitis Profile Con Hepatitis B Monito Human Papillomas Liver Function Panel Co Megaloblastic Anemi Prenatal Evaluatio Premantal, Male Profactin, Serum Profein Electroph.	Diagnostic 04012-8	Prenatal Profile. Ro Prenatal Profile. Com Prostate Panel. Dia T-Helger/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyd CIMEN (A) =ROX Vitamin B12 & Fola
D4001-8: Master Chem D6005 Anthritis Profile. Routine D7402 Anthritis Profile. Routine D7402 Anthritis Profile Comprenensive D7406-3: CARE. Panel #1 D6905-8: CARE. Panel #2 D6846-4: CARE. Panel #3 UNLESS OTHERWISE STATED PLEAS D2500-3: ABO Group & Rh Type D0287-1: Acid Phosphatase. Prostatic (F) D3453 Acid Phosphatase. Total (F) D0074-8: Alkaline Phosphatase	07702-2 Compler 06202-9 Compreh 06324 Electroly 04003 Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 01200-1 Glucose 00110-0 HCG, Se	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II ecutive Profile H Evaluation INDIV 1 hr 'pp erum Qual erum Quant	07855-1	Hepatitis Profile Co Hepatitis Profile Con Hepatitis B Monito Human Papillomas Liver Function Panel Co Megalobiastic Anemi Prenatal Evaluatio Premantal, Male Profactin, Serum Profein Electroph. Profitrombin Time	Diagnostic 04012-8	Prenatal Profile. Ri Prenatal Profile. Com Prostate Panel. Dia T-Helder/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp CIMEN (B) =ROC Vitamin B12 & Fola IICRCBIOLOGY
D4001-8: Master Chem D6005 Anthritis Profile. Routine D7402 Anthritis Profile. Routine D7402 Anthritis Profile Comprenensive D7406-3: CARE Panel #1 D6905-8: CARE Panel #2 D6846-4: CARE Panel #3 UNLESS OTHERWISE STATED PLEAS D2500-3: ABO Group & Rh Type D0287-1: Acid Phosphatase. Prostatic (F) D0453 Acid Phosphatase. Total (F) D0074-8: Alkaline Phosphatase	07702-2 Compler 06202-9 Compreh 06324 Electroly 04003 Executiv 04005-1 Mini-Exe 03008-5 FSH & L 01201-2 Glucose 01200-1 Glucose 00110-0 HCG, Se 00005-5 HDL Chc	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II ecutive Profile H Evaluation INDIV 1 hr 'so 2 hr PP erum Qualt erum Quant plesterol	07855-1	Hepatitis Profile Cor Hepatitis Profile Cor Hepatitis B Monito Human Papillomas Liver Function Panel Co Megaloblastic Anemi Prenatal Evaluatio Premarital, Male Profactin, Serum Profen Electroph, Profile PSA	Diagnostic 04012-8	Prenatal Profile. Ri Prenatal Profile. Com Prostate Panel. Dia T-Helder/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp CIMEN (A) = ROC Vitamin B12 & Fola IICRCBIOLOGY
D4001-8: Master Chem D6005 Anthritis Profile. Routine D7402 Anthritis Profile. Routine D7402 Anthritis Profile Comprenensive D7406-3: CARE. Panel #1 D6905-8: CARE. Panel #2 D6846-4: CARE. Panel #3 UNLESS OTHERWISE STATED PLEAS D2500-3: ABO Group & Rh Type D0287-1: Acid Phosphatase. Prostatic (F) D3453 Acid Phosphatase. Total (F) D0074-8: Alkaline Phosphatase	07702-2 Compler 06202-9 Compreh 06324 Electroly 04003 Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 01200-1 Glucose 00110-0 HCG, Se	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II ecutive Profile H Evaluation INDIV 1 hr 'pp erum Qual erum Quant plesterol poin A1C	07855-1	Hepatitis Profile Cor Hepatitis Profile Cor Hepatitis B Monito Human Papillomas Liver Function Panel Co Megaloblastic Anemi Prenatal Evaluatio Premarital, Male Profactin, Serum Profen Electroph, Profile PSA	Diagnostic 04012-8	Prenatal Profile. Ri Prenatal Profile. Com Prostate Panel. Dia T-Helder/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp CIMEN (A) = ROC Vitamin B12 & Fola IICRCBIOLOGY
D4001-8: Master Chem D6005 Anthritis Profile. Routine D7402 Anthritis Profile. Routine D7402 Anthritis Profile Comprenensive D7406-3: CARE. Panel #1 D6905-8: CARE. Panel #2 D6846-4: CARE. Panel #3 UNLESS OTHERWISE STATED PLEAS D2500-3: ABO Group & Rh Type D0287-1: Acid Phosphatase. Prostatic (F) D3453 Acid Phosphatase. Total (F) D0074-8: Alkaline Phosphatase	07702-2 Compler 06202-9 Compreh 06324 Electroly 04003 Executiv 04005-1 Mini-Exe 03008-5 FSH & L 01201-2 Glucose 01200-1 Glucose 00110-0 HCG, Se 004701-4 Hemogic	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II cutive Profile M Evaluation INDIVI . 1 hr 'pp erum Qual erum Quant plesterol poin A1C am	07855-1	Hepatitis Profile Co Hepatitis Profile Con Hepatitis B Monito Human Papilloma Liver Function Panel Co Megalobiastic Anemi Prenatal Evaluatio Premantal, Male Profactin, Serum Protein Electroph, Profirombin Time PSA PTT	Diagnostic 04012-8	Prenatal Profile. Ri Prenatal Profile. Com Prostate Panel. Dia T-Helcer/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp CIMEN (B) =ROX Vitamin B12 & Fola IICRCBIOLOGY Culture. Urine Culture. Gental Culture. GC Screen
D4001-8: Master Chem D6005 Anthritis Profile. Routine D7402 Anthritis Profile. Routine D7402 Anthritis Profile Comprenensive D7406-3: CAR.E. Panel #1 D6905-8: CAR.E. Panel #2 D6846-4: CAR.E. Panel #3 UNLESS OTHERWISE STATED PLEAS D2500-3: A80 Group & Rh Type D2500-3: Acid Phosphatase. Prostatic (F) D3453 Acid Phosphatase. Total (F) D0074-8: Alkaline Phosphatase D0068-2: Amylase. Serum D0037-4: ANA D0162-8: ASO Titer	07702-2 Compler 06202-91 Compren 06324- Electroly 04003- Executiv 04005-1 Mini-Exe 03008-5 FSH & L 6E REFRIGERATE 01201-2 Glucose 00110-0 HCG. Se 00005-5 HDL Chc 04701-4 Hemogic	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II ecutive Profile H Evaluation INDIV 1 hr 'so 2 hr PP erum Quant plesterol poin A1C am ant	07855-1	Hepatitis Profile Co Hepatitis Profile Con Hepatitis B Monito Human Papilloma Liver Function Panel Co Megalobiastic Anemi Prenatal Evaluatio Premantal, Male Profactin, Serum Protein Electroph, Profirombin Time PSA PTT Reticulocyte Coun Rheumatoid Facto	Diagnostic 04012-8	Prenatal Profile. Ri Prenatal Profile. Com Prostate Panel. Dia T-Helcer/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp CIMEN (A) = ROC Vitamin B12 & Fola IICRCBIOLOGY Culture. Urine Culture. Gental Culture. GC Screen Culture. Throat or S
D4001-8: Master Chem D5005 Anhritis Profile. Routine D7402 Anhritis Profile. Routine D7402 Anhritis Profile Comprenensive D7406-3: CARE. Panel #1 D6905-8: CARE. Panel #2 D6846-4: CARE. Panel #2 D8846-4: CARE. Panel #3 UNLESS OTHERWISE STATED PLEAS D2500-3: A80 Group & Rh Type D0287-1: Acid Phosphatase. Prostatic (F) D0453 Acid Phosphatase. Prostatic (F) D0074-8: Akidine Phosphatase D0068-2: Amylase. Serum D0037-4: ANA D0162-8: ASO Titer D0072-6: Bilirubin. Tot & Direct D0019-8: BUN D0560 Carbamazepine	07702-2 Compler 06202-9 Compreh 06324 Electroly 04003 Executiv 04005-1 Mini-Exe 03008-5 FSH & L 6E REFRIGERATE 01201-2 Glucose 00110-0 HCG. Se 00005-5 HDL Chc 04701-4 Hemogic 007853 Hemogu	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II ecutive Profile H Evaluation INDIVI . 1 hr 'sp . 2 hr PP erum Qualt erum Quant blesterol boin A1C am ant B, IGG & IGM Gurlace AG	07855-1	Hepatitis Profile Collegatitis Profile Collegatitis Profile Collegatitis B Monito Human Papillomas Liver Function Panel Collegatitis Anemi Prenatal Evaluatio Premarital, Male Profactin, Serum Protein Electroph. Prothrombin Time PSA PTT Reticulocyte Coun Rheumatoid Facto RPR Rubella Antibody	Diagnostic 04012-8	Prenatal Profile. Ri Prenatal Profile. Com Prostate Panel. Dia T-Helcer/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp CIMEN (B) = ROX Vitamin B12 & Fola IICRCBIOLOGY Culture. Urine Culture. Genital Culture. GC Screen Culture. Strep Scre Culture. Strep Scre Culture. Stool
D4001-8: Master Chem D5005 Anhritis Profile. Routine D7402 Anhritis Profile. Routine D7402 Anhritis Profile. Routine D7402 Anhritis Evaluation II D8006-0. Anhritis Profile Comprenensive D7406-3: C.A.R.E. Panel #1 D8905-8: C.A.R.E. Panel #2 D8846-4: C.A.R.E. Panel #2 D8846-4: C.A.R.E. Panel #3 UNLESS OTHERWISE STATED PLEAS D2500-3: A80 Group & Rh Type D2500-3: Acid Phosphatase. Prostatic (F) D3453 Acid Phosphatase. Prostatic (F) D3453 Acid Phosphatase. Prostatic (F) D3074-8: Akidine Phosphatase D0068-2: Amylase. Serum D0037-4: ANA D162-8: ASO Titer D0072-6: Bilirubin. Tot & Direct D0019-8: BUN D0560 Carbamazepine D0063-8. CBC	07702-2 Compler 06202-9 Compreh 06324 Electroly 04003 Executiv 04005-1 Mini-Exe 03008-5 FSH & L 6E REFRIGERATE 01201-2 Glucose 00110-0 HCG. Se 00005-5 HDL Che 04701-4 Hemogic 007853 Hemoau 00523-6 Heo A A 00060-5 Heo B. S	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II ecutive Profile H Evaluation INDIVI . 1 hr 'sp . 2 hr PP erum Qualt erum Quant blesterol boin A1C am ant B, IGG & IGM Gurlace AG urlace AB	07855-1	Hepatitis Profile. Co Hepatitis Profile. Cor Hepatitis B Monito Human Papillomai Liver Function Panel. Co Megaloblastic Anemi Prenatal Evaluatio Premarital. Male Profactin. Serum Protein Electroph Prothrombin Time PSA PTT Reticulocyte Coun Rheumatoid Facto RPR Rubella Antibody Sed Rate (ESR), V	Diagnostic 04012-8	Prenatal Profile. Richard Profile. Richard Profile. Compression Prostate Panel. Dia T-Helder/T-Suppression Panel. Hypotherical Panel. Profile. Richard Profile. P
D4001-8: Master Chem D5005 Anthritis Profile. Routine D7402 Anthritis Profile. Routine D7402 Anthritis Profile. Routine D7402 Anthritis Evaluation II D8006-0. Anthritis Profile Comprenensive D7406-3. C.A.R.E. Panel #1 D8905-8. C.A.R.E. Panel #2 D8846-4. C.A.R.E. Panel #3 UNLESS OTHERWISE STATED PLEAS D2500-3. A80 Group & Rh Type D2500-3. A80 Group & Rh Type D2500-3. Acid Phosphatase. Prostatic (F) D3453 Acid Phosphatase. Prostatic (F) D0074-8. Aikaline Phosphatase D0068-2. Amylase. Serum D0037-4. ANA D0162-8. ASO Titer D0072-6. Bilirubin. Tot & Direct D0019-8. BUN D0560 Carbamazepine D0063-8. CBC D0092-41. CEA	07702-2 Compler 06202-9 Compren 06324- Electroly 04003- Executiv 04018-3 Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 001200-1 Glucose 00110-0 HCG. Se 00005-5 HDL Che 04701-4 Hemogra 07853- Hemodu 00523-6 Hep A A 00050-5 Hep B S 01310-1 Hep B S	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II ecutive Profile H Evaluation INDIVI . 1 hr 'pp erum Qual erum Quant plesterol poin A1C am ant B, IGG & IGM Gurlace AB urlace AB	07855-1	Hepatitis Profile. Cor Hepatitis Profile Cor Hepatitis B Monito Human Papilloma Liver Function Panel. Co Megaloblastic Anemi Prenatal Evaluatio Premarital. Male Profactin. Serum Profein Electroph. Profirombin Time PSA PTT Reticulocyte Coun Rheumatoid Facto RPR Rubella Antibody Sed Rate (ESR), V Sickle Cell Screen	Diagnostic 04012-8	Prenatal Profile. Ro Prenatal Profile. Com Prostate Panel. Dia T-Hetcer/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp CIMEN @=ROC Vitamin 812 & Fola IICRCBIOLOGY Culture. Urine Culture. Genital Culture. Genital Culture. Strep Scre Culture. Strep Scre Culture. Stool Culture. Rectal: GC/At Culture. Wound
DA001-8	07702-2 Compler 06202-9 Compren 06324- Electroly 04003- Executiv 04018-3 Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 001200-1 Glucose 00110-0 HCG. Se 00005-5 HDL Cho 04701-4 Hemogra 07853- Hemodu 00523-6 Hep A A 00050-5 Heo B S 01310-1 Heo B S 07895-8 Hivagen 03381-4 HIV Antil	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II cutive Profile M Evaluation INDIVI . 1 hr 'pp erum Qual erum Quant plesterol poin A1C am ant 8. IGG & IGM surface AG urface AB	07855-1	Hepatitis Profile. Cor Hepatitis Profile Cor Hepatitis B Monito Human Papilloma Liver Function Panel. Co Megaloblastic Anemi Premartal Evaluatio Premarital. Male Profactin. Serum Profein Electroph Profirmbin Time PSA PTT Reticulocyte Coun Rheumatoid Facto RPR Rubella Antibody Sed Rate (ESR), v Sickle Cell Screen SGOT (AST)	Diagnostic 04012-8	Prenatal Profile. Ro Prenatal Profile. Com Prostate Panel. Dia T-Hetcer/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp CliMEN (B) =ROC Vitamin B12 & Fola IICRCBIOLOGY Culture. Genital Culture. GC Screen Culture. GC Screen Culture. Throat or S Culture. Stool Culture. Rectal: GC/Al Culture. Wound Culture. Wound Culture. Other
DAMPS Master Chem	07702-2 Compler 06202-9 Compren 06324- Electroly 04003- Executiv 04018-3 Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 001200-1 Glucose 00110-0 HCG. Se 00005-5 HDL Cho 04701-4 Hemogra 07853- Hemodu 00523-6 Hep A A 00050-5 Heo B S 01310-1 Heo B S 07895-8 Hivagen 03381-4 HIV Antil	me Evaluation ment Evaluation ensive Health Evalu the Panel the Profile I the Profile II the Pro	07855-1	Hepatitis Profile. Cor Hepatitis Profile Cor Hepatitis B Monito Human Papilloma Liver Function Panel. Co Megaloblastic Anemi Prenatal Evaluatio Premarital. Male Profactin. Serum Protein Electroph. Prothrombin Time PSA PTT Reticulocyte Coun Rheumatoid Facto RPR Rubella Antibody Sed Rate (ESR). V Sickle Cell Screen SGOT (AST) SGPT (ALT)	Diagnostic 04012-8	Prenatal Profile. Ro Prenatal Profile. Com Prostate Panel. Dia T-Hetcer/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp Climen 812 & Fola IICRCBIOLOGY Culture. Urine Culture. Genital Culture. Genital Culture. Throat or S Culture. Stool Culture. Rectal: GC/Al Culture. Pectal: GC/Al Culture. Wound Culture. Other Culture. Blood
DAMPS Master Chem	07702-2 Compler 06202-9 Compren 06324- Electroly 04003- Executiv 04018-3 Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 001200-1 Glucose 00110-0 HCG. Se 00005-5 HDL Cho 04701-4 Hemogra 07853- Hemodu 00523-6 Hep A A 00060-5 Hep B S 07895-8 Hivagen 03381-4 HIV Antil 00393-8 Immunoo 00064-9 Iron & Ti	me Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II cutive Profile M Evaluation INDIVI . 1 hr 'pp erum Qual erum Quant plesterol poin A1C am ant 8. IGG & IGM surface AG urface AB bodies, Screen glob G.A.M. BC	07855-1	Hepatitis Profile. Cor Hepatitis Profile Cor Hepatitis B Monito Human Papilloma Liver Function Panel. Co Megaloblastic Anemi Prenatal Evaluatio Premarital. Male Profactin. Serum Protein Electroph Prothrombin Time PSA PTT Reticulocyte Coun Rheumatoid Facto RPR Rubella Antibody Sed Rate (ESR). V Sickle Cell Screen SGOT (AST) SGPT (ALT) T3 Uptake	Diagnostic 04012-8	Prenatal Profile. Ro Prenatal Profile. Com Prostate Panel. Dia T-Hetcer/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp Climen B12 & Fola ICRCBIOLOGY Culture. Urine Culture. Genital Culture. Genital Culture. Throat or S Culture. Stool Culture. Rectal: GC/Al Culture. Wound Culture. Other Culture. Blood Culture. Blood Culture. Blood
DAMPS Master Chem	07702-2 Compler 06202-9 Compren 06324- Electroly 04003- Executiv 04018-3 Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 001200-1 Glucose 00110-0 HCG. Se 00005-5 HDL Cho 04701-4 Hemogra 07853- Hemodu 00523-6 Hep A A 00050-5 Heo B S 01310-1 Heo B S 07895-8 Hivagen 03381-4 HIV Antil	me Evaluation ment Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II ecutive Profile H Evaluation INDIVI 1 hr op 2 hr PP erum Qualt erum Quant plesterol poin A1C am ant B IGG & IGM ourlace AG urlace AG urlace AB bodies, Screen glob G.A.M. BC enzymes (R)	07855-1	Hepatitis Profile. Cor Hepatitis Profile Cor Hepatitis B Monito Human Papilloma Liver Function Panel. Co Megaloblastic Anemi Prenatal Evaluatio Premarital. Male Profactin. Serum Protein Electroph. Prothrombin Time PSA PTT Reticulocyte Coun Rheumatoid Facto RPR Rubella Antibody Sed Rate (ESR). V Sickle Cell Screen SGOT (AST) SGPT (ALT) T3 Uptake T3, RIA	Diagnostic 04012-8	Prenatal Profile. Richeratal Profile. Romeratal Profile. Compressive Panel. Did T-Helcer/T-Suppress Thyroid Panel. Hypoid Panel.
DA001-8 Master Chem	07702-2 Compler 06202-9 Compren 06324- Electroly 04003- Executiv 04018-3 Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 001200-1 Glucose 00110-0 HCG. Se 00005-5 HDL Chd 04701-4 Hemogra 07853- Hemogra 07853- Hep A A 00060-5 Hep B S 07895-8 Hivagen 03381-4 HIV Antil 00393-8 Immunod 00064-9 Iron & Ti 00064-9 Iron & Ti	me Evaluation ment Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II ecutive Profile H Evaluation INDIVI 1 hr op 2 hr PP erum Qualt erum Quant plesterol poin A1C am ant B IGG & IGM ourlace AG urlace AG urlace AB bodies, Screen glob G.A.M. BC enzymes (R)	07855-1	Hepatitis Profile. Cor Hepatitis Profile Cor Hepatitis B Monito Human Papilloma Liver Function Panel. Co Megaloblastic Anemi Prenatal Evaluatio Premarital. Male Profactin. Serum Protein Electroph. Prothrombin Time PSA PTT Reticulocyte Coun Rheumatoid Facto RPR Rubella Antibody Sed Rate (ESR). V Sickle Cell Screen SGOT (AST) SGPT (ALT) T3 Uptake T3, RIA	Diagnostic 04012-8	Prenatal Profile. Ro Prenatal Profile. Com Prostate Panel. Dia T-Hetcer/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp Climen B12 & Fola ICRCBIOLOGY Culture. Urine Culture. Genital Culture. Genital Culture. Stool Culture. Stool Culture. Rectal: GC/Al Culture. Other Culture. Other Culture. Herpes Culture. Herpes Culture. Chlamydia Culture. Chlamydia Culture. Chlamydia Culture. Fungus
DA001-8 Master Chem	07702-2 Compler 06202-9 Compren 06324- Electroly 04003- Executiv 04003- Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 001200-1 Glucose 00110-0 HCG. Se 00005-5 HDL Che 04701-4 Hemogra 07853- Hemogra 07853- Hep A A 00050-5 Hep B S 01310-1 Hep B S 07895-8 Hivagen 03381-4 HIV Antil 00393-8 Immunoc 00064-9 Iron & TI 00047-3 LDH. Iso 00046-2 LDH. Se	me Evaluation ment Evaluation ensive Health Evalu ite Panel re Profile I re Profile II recutive Profile M Evaluation INDIVI 1 hr op 2 hr PP rum Qualt rum Quant olesterol obin A1C am ant 8. IGG & IGM ourlace AB boodies. Screen glob G.A.M. BC enzymes (R) rum	07855-1	Hepatitis Profile. Collegatitis Prenatal Evaluation. Megaloblastic Anemin Prenatal Evaluation. Premarital. Male Profactin. Serum Profess Electroph. Profitrombin Time PSA PTT Reticulocyte Coun Rheumatoid Factor RPR Rubella Antibody. Sed Rate (ESR). V. Sickle Cell Screen SGOT (AST). SGPT (ALT). T3 Uptake. T3. RIA. Testosterone. Seru Theophylline.	Diagnostic 04012-8	Prenatal Profile. Ro Prenatal Profile. Com Prostate Panel. Dia T-Hetcer/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp Climen B12 & Fola Vitamin B12 & Fola IICRCBIOLOGY Culture. Urine Culture. Genital Culture. Genital Culture. Stool Culture. Stool Culture. Rectal: GC/Al Culture. Other Culture. Other Culture. Herpes Culture. Chlamydia Culture. Chlamydia Culture. Fungus Culture. Fungus Culture. Fungus
DA001-8	07702-2 Compler 06202-9 Compren 06324- Electroly 04003- Executiv 04003- Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 001200-1 Glucose 00110-0 HCG. Se 00005-5 HDL Chd 04701-4 Hemogra 07853- Hemogra 07853- Hep A A 00060-5 Hep B S 07895-8 Hivagen 03381-4 HIV Antil 00393-8 Immunoc 00047-3 LDH. Iso 00047-3 LDH. Iso 000472- Phenoba	me Evaluation ment Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II ecutive Profile H Evaluation INDIVI 1 hr op 2 hr PP erum Quant plesterol poin A1C am ant B, IGG & IGM surface AB urface AB bodies, Screen glob G,A,M, BC enzymes (R) rum reen uroital	07855-1	Hepatitis Profile. Collegatitis Prenatal Evaluation Prenatal Evaluation Prenatal Evaluation Profile. Collegatitis Profile. Profile. Serum Profile. Serum Profile. Pr	Diagnostic 04012-8	Prenatal Profile. Ro Prenatal Profile. Com Prostate Panel. Dia T-Hetcer/T-Suppress Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp Thyroid Panel. Hyp Climen B12 & Fola ICRCBIOLOGY Culture. Urine Culture. Genital Culture. Genital Culture. Throat or S Culture. Stool Culture. Rectal: GC/Al Culture. Other Culture. Other Culture. Herpes Culture. Chlamydia Culture. Chlamydia Culture. Fungus Culture. Fungus Culture. Fungus Culture. Fungus
DA001-8 Master Chem	07702-2 Compler 06202-9 Compren 06324- Electrolv 04003- Executiv 04003- Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 001200-1 Glucose 00110-0 HCG. Se 00005-5 HDL Chd 04701-4 Hemogra 07853- Hemogra 07853- Hep A A 00060-5 Hep B S 07895-8 Hivagen 03381-4 HIV Antil 00393-8 Immunoc 00047-3 LDH. Iso 00047-3 LDH. Iso 000472- Phenoba 00089-1 Phenoto	me Evaluation ment Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II ecutive Profile H Evaluation INDIVI 1 hr op 2 hr PP erum Qualt erum Quant plesterol poin A1C am ant B. IGG & IGM ourlace AG urface AG urface AG profile II ecutive Profile erum Quant plesterol poin A1C am ant B. IGG & IGM ourlace AG urface AG urface AG urface AG profile II ecutive Profile enzymes (R) rum	07855-1	Hepatitis Profile. Collegatitis Prenatal Evaluation. Premarital. Male Profactin. Serum Profile. Electroph. PSA PTT Reticulocyte Count Rheumatoid Factor Reticulocyte Profile. Electrophylline Triglycerides TSH	Diagnostic 04012-8	Prenatal Profile. Ro Prenatal Profile. Ro Prenatal Profile. Com Prostate Panel. Dia T-Hetcer/T-Suppress Thyroid Panel. Hyp CollMEN (B) = ROC Vitamin B12 & Fola IICRCBIOLOGY Culture. Urine Culture. Genital Culture. Genital Culture. Strep Scree Culture. Strep Scree Culture. Strep Scree Culture. Rectal: GC/Al Culture. Other Culture. Other Culture. Herpes Culture. Chlamydia Culture. Fungus Culture. AFB & Smituman Papillomavirus Dva & Parassles (x1) Cocult Blood (x1)
DA001-8 Master Chem	07702-2 Compler 06202-9 Compren 06324- Electroly 04003- Executiv 04003- Executiv 04005-1 Mini-Exe 03008-5 FSH & L SE REFRIGERATE 01201-2 Glucose 001200-1 Glucose 00110-0 HCG. Se 00005-5 HDL Chd 04701-4 Hemogra 07853- Hemogra 07853- Hep A A 00060-5 Hep B S 07895-8 Hivagen 03381-4 HIV Antil 00393-8 Immunoc 00047-3 LDH. Iso 00047-3 LDH. Iso 000472- Phenoba	me Evaluation ment Evaluation ment Evaluation ensive Health Evalu ite Panel e Profile I e Profile II cutive Profile H Evaluation INDIV 1 hr 'pp erum Qual erum Quant plesterol poin A1C am ant B. IGG & IGM surface AG urface AG urface AG urface AG enzymes (R) rum reen uroital n (Oilantin) m. Serum	07855-1	Hepatitis Profile. Collegatitis Prenatal Evaluation Prenatal Evaluation Prenatal Evaluation Profile. Collegatitis Profile. Profile. Serum Profile. Serum Profile. Pr	Diagnostic 04012-8	Prostate Panel. Dia T-Hetcer/T-Suppress Thyroid Panel. Hypotheric

EX-ERPTION: Unrecognized Physical Illness Prompting Psychiatric Admission: A Prospective Study (from 1980 APA Convention)

Page O (Abstract)

This study of ICC consecutive state hospital psychiatric patients admitted to a research ward, who were screened to eliminate physical illness prior to admission, suggests an unusually high incidence of significant medical illness...Forty six percent of these patients had a previously unrecognized medical illness which either caused or exacerbated their psychiatric illness. Eighty percent of the patients had physical illnesses requiring treatment.

...The implication of these findings for psychiatric training and hospital psychiatry are discussed, as are the legal implications and possible effects upon the profession as a whole.

Page I

It is well known that psychiatric symptoms are not illness specific and may be caused by a wide variety of medical as well as psychiatric diseases. Psychiatric patients have been shown to be athigh risk for both increased physical morbidity and mortality....the fact that underlying medical disease can produce symptoms usually considered to be purely psychogenic remains notably underestimated...pshysical illnesses may present purely as depression, anxiety states, apathy, aggressive outbursts, personality changes, sexual dysfunctions, delusions, hallucinations, or as schizophreniform or manic-like psychotic states....Koranyi...was able to demonstrate that 20% of ICO consecutive outpatients seen at his clinic had medical illnesses which proved to be the sole and exclusive cause of their initial psychiatric symptoms. Pokorny and Frazier, in I966...Six Hundred and ninety-one of those I530 patients were found to have significant medical illness.

Page 2 (METHOD)

During the screening interview, a careful psychiatric and medical history and detailed mental status examination were obtained, and previous hospital records, if available, were scrutinized. Patients with known physical disorders were excluded from the study, as were patients with sociopathic personality disorders and significant histories of alcohol or drug abuse.